0001932393-23-000087 | 10-Q | XBRL Viewer | GE Healthcare Technologies INC

Print Document View Excel Document

SUBSEQUENT EVENTS	3 Months Ended
SUBSEQUENT EVENTS	Mar. 31, 2023
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	SUBSEQUENT EVENTSOn April 25th, 2023 the Company’s Board of Directors declared a cash dividend of $0.03 per share of common stock, payable on June 15, 2023, to stockholders of record on May 23, 2023.

BORROWINGS - Narrative (Details)		3 Months Ended
BORROWINGS - Narrative (Details)	Jan. 03, 2023 USD ($)	Mar. 31, 2023 USD ($) series	Dec. 31, 2022 USD ($)
Debt Instrument [Line Items]
Debt repayments		$ 0
Guarantor obligations, maximum exposure		164,000,000
Guarantee obligation, carrying value		4,000,000	$ 4,000,000
Commercial contracts
Debt Instrument [Line Items]
Guarantor obligations, maximum exposure		675,000,000	657,000,000
Equipment residual value obligation
Debt Instrument [Line Items]
Guarantor obligations, maximum exposure		44,000,000	43,000,000
Senior notes \| Senior unsecured notes
Debt Instrument [Line Items]
Debt, principal amount		$ 8,250,000,000
Number of debt series \| series		6
Line of credit \| Revolving credit facility
Debt Instrument [Line Items]
Line of credit outstanding		$ 0	$ 0
Line of credit \| Revolving credit facility \| 5-Year Revolving Credit Facility
Debt Instrument [Line Items]
Debt, term		5 years
Maximum borrowing capacity		$ 2,500,000,000
Line of credit \| Revolving credit facility \| 364-Day Revolving Credit Facility
Debt Instrument [Line Items]
Debt, term		364 days
Maximum borrowing capacity		$ 1,000,000,000
Line of credit \| Unsecured debt \| Term Loan Facility
Debt Instrument [Line Items]
Debt, term		3 years
Maximum borrowing capacity		$ 2,000,000,000
Proceeds from lines of credit	$ 2,000,000,000
Line of credit, average interest rate		5.94%

EARNINGS PER SHARE - Schedule of Earnings per Share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Numerator:
Net income	$ 383	$ 402
Net (income) attributable to noncontrolling interests	(11)	(13)
Net income attributable to GE HealthCare	372	389
Deemed preferred stock dividend of redeemable noncontrolling interest	(183)	0
Net income attributable to GE HealthCare common stockholders	$ 189	$ 389
Denominator:
Basic weighted-average shares outstanding	454	454
Dilutive effect of common stock equivalents (in shares)	3	0
Diluted weighted-average shares outstanding	457	454
Basic earnings per share (in dollars per share)	$ 0.42	$ 0.86
Diluted earnings per share (in dollars per share)	$ 0.41	$ 0.86
Antidilutive securities (in shares)	4	0

RESTRUCTURING AND OTHER ACTIVITIES

3 Months Ended

Mar. 31, 2023

Restructuring and Related Activities [Abstract]

RESTRUCTURING AND OTHER ACTIVITIES

Restructuring activities are essential to reflect the business operating model for GE HealthCare as a stand-alone company and mostly involve workforce reductions, organizational realignments, and revisions to our real estate footprint. Specifically, restructuring and other charges primarily include facility exit costs, employee-related termination benefits associated with workforce reductions, asset write-downs, and cease-use costs. For segment reporting, restructuring, and other activities are not allocated.

As a result of committed restructuring initiatives, we recorded expenses of $12 million for both the three months ended March 31, 2023 and 2022. These restructuring initiatives are expected to result in additional expenses of approximately $71 million, to be incurred primarily in 2023, substantially related to employee-related termination benefits and facility exit costs. Restructuring expenses are recognized within Cost of products, Cost of services, or Selling, general, and administrative ("SG&A"), as appropriate, in the Condensed Consolidated and Combined Statements of Income.


Restructuring and Other Activities
	For the three months ended March 31
	2023		2022
Employee termination costs	$	10	$	9
Facility and other exit costs	1		3
Asset write-downs	1		—
Total restructuring and other activities	$	12	$	12

In connection with the Spin-Off, GE transferred employee termination obligations for services already rendered of $31 million to GE HealthCare. Liabilities related to restructuring are recognized within All other current liabilities and All other liabilities in the Condensed Consolidated and Combined Statements of Financial Position and totaled $99 million and $75 million as of March 31, 2023 and December 31, 2022, respectively.

RELATED PARTIES

3 Months Ended

Mar. 31, 2023

RELATED PARTIES

PRIOR TO SPIN-OFF.

Prior to the Spin-Off, GE provided the Company with significant corporate infrastructure and shared services. Some of these services will continue to be provided by GE to the Company on a temporary basis under the Transition Services Agreement, as discussed below. The following disclosures summarize related party activity between GE HealthCare and GE. This activity, which occurred prior to the Spin-Off, is included in the condensed combined financial statements.

Pensions, Benefit, and Contribution Plans

As discussed in Note 9, “Postretirement Benefit Plans,” employees of the Company participated in pensions, benefit, and contribution plans that were sponsored by GE. The Company was charged $59 million for the three months ended March 31, 2022 related to employee participation in these plans. In connection with the Spin-Off, a portion of these plans were transferred to the Company.

Share-based Compensation

GE granted various employee benefits to its group employees, including those of the Company, under the GE Long-Term Incentive Plan. These benefits primarily included stock options and restricted stock units. Compensation expense allocated to the Company was $19 million for the three months ended March 31, 2022, and is recognized within SG&A in the Condensed Combined Statement of Income.

Corporate Overhead and Other Allocations from GE

GE provided certain services described below that were charged to the Company based on employee headcount, revenue, or other allocation methodologies.


Corporate Allocations from GE
	March 31, 2022
Costs for centralized services(a)	$	13
Costs associated with employee medical insurance(b)	30
Costs for corporate and shared services(c)	116

(a) Costs for centralized services such as public relations, treasury and cash management, and other services were recognized within SG&A in the Condensed Combined Statement of Income.

(b) Costs associated with employee medical insurance were recognized within Cost of products, Cost of services, SG&A, and Research and development ("R&D") in the Condensed Combined Statement of Income based on the employee population.

(c) Costs for corporate and shared services such as information technology, finance and other services were primarily recognized in SG&A and R&D in the Condensed Combined Statement of Income.

Management believes that the expense and cost allocations have been determined on a basis that is a reasonable reflection of the utilization of services provided or the benefit received by the Company during the three months ended March 31, 2022. The amounts that would have been, or will be incurred, on a stand-alone basis could materially differ from the amounts allocated due to economies of scale, difference in management judgment, a requirement for more or fewer employees, or other factors.

AFTER SPIN-OFF.

In connection with the Spin-Off, the Company entered into or adopted several agreements that provide a framework for the relationship between the Company and GE, including, but not limited to the following which had activity during the first quarter of 2023:

•Separation and Distribution Agreement – sets forth the principal actions to be taken in connection with the Spin-Off, including the transfer of assets and assumption of liabilities, and establishes certain rights and obligations between the Company and GE following the Distribution, including procedures with respect to claims subject to indemnification and related matters..

•Transition Services Agreement – governs all matters relating to the provision of services between the Company and GE on a transitional basis. The services the Company receives include support for digital technology, human resources, supply chain, finance, and real estate services, among others. The services generally commenced on the date of the Spin-Off and will terminate up to 36 months following the Distribution Date depending upon the related transitional service. For the three months ended March 31, 2023, we incurred $108 million, net, which represents fees charged from GE to the Company primarily for information technology, human resources, and R&D and is net of fees charged from the Company to GE for facilities and other shared services.

•Tax Matters Agreement (“TMA”) – governs the respective rights, responsibilities, and obligations between the Company and GE with respect to all tax matters (excluding employee-related taxes covered under the Employee Matters Agreement), in addition to certain restrictions which generally prohibit us from taking or failing to take any action in the two-year period following the Distribution that would prevent the Distribution from qualifying as tax-free for U.S. federal income tax purposes, including limitations on our ability to pursue certain strategic transactions. The TMA specifies the portion of tax liability for which the Company will bear contractual responsibility, and the Company and GE will each agree to indemnify each other against any amounts for which such indemnified party is not responsible.

Current amounts due from and to GE under the various agreements described above are recognized within Due from related parties or Due to related parties, as applicable, in the Condensed Consolidated and Combined Statements of Financial Position. Non-current amounts due from and to GE were $77 million and $108 million, respectively, as of March 31, 2023 and were recognized within All other assets or All other liabilities, as applicable, in the Condensed Consolidated Statements of Financial Position. These amounts primarily relate to tax and other indemnities.

GE HealthCare sells products and services in the ordinary course of business to certain entities associated with two members of our Board of Directors. During the three months ended March 31, 2023, we recognized revenue of $24 million from these entities in connection with providing products and services. Current amounts due from these entities as of March 31, 2023 were not significant.

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS

3 Months Ended

Mar. 31, 2023

Fair Value Disclosures [Abstract]

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS

DERIVATIVES AND HEDGING.

Our primary objective in executing and holding derivatives is to reduce the earnings and cash flow volatility associated with fluctuations in foreign currency exchange rates and commodity prices and hedge the volatility associated with the translation of the assets and liabilities of subsidiaries with a different functional currency than the USD. These hedge contracts reduce, but do not entirely eliminate, the impact of foreign currency rate and commodity price movements. The Company does not enter into or hold derivative instruments for speculative trading purposes.

Cash Flow Hedges

The total amount in AOCI related to cash flow hedges of foreign currency-denominated forecasted transactions was a net $30 million loss as of March 31, 2023. We expect to reclassify $27 million of pre-tax net deferred losses associated with designated cash flow hedges to earnings in the next 12 months, contemporaneously with the earnings effects of the related forecasted transactions. Pre-tax gains (losses) reclassified from AOCI into earnings were $33 million and $11 million, for the three months ended March 31, 2023 and 2022, respectively. As of March 31, 2023, the maximum length of time over which we are hedging our forecasted transactions was approximately two years.

Net Investment Hedges

As of March 31, 2023 and December 31, 2022, the Company had $2,176 million and $2,132 million notional, respectively, of receive-fixed USD, pay-fixed Euro (“EUR”) cross-currency swaps and designated each as the hedging instruments in net investment hedging relationships in order to mitigate the foreign currency risk attributable to the translation of its net investment in certain EUR-functional subsidiaries.

The following table presents the gross fair values of our outstanding derivative instruments as of the dates indicated:


Fair Value of Derivatives
	March 31, 2023						December 31, 2022
	Gross Notional		Fair Value – Assets		Fair Value – Liabilities		Gross Notional		Fair Value – Assets		Fair Value – Liabilities
Foreign currency exchange contracts	$	1,226	$	25	$	62	$	1,240	$	32	$	53
Derivatives accounted for as cash flow hedges	1,226		25		62		1,240		32		53
Cross-currency swaps	2,176		21		167		2,132		—		111
Derivatives accounted for as net investment hedges	2,176		21		167		2,132		—		111
Foreign currency exchange contracts	4,690		38		22		4,456		9		20
Embedded derivatives	594		19		14		604		24		18
Equity contracts	231		15		3		8		—		6
Commodity derivatives	54		1		3		48		1		1
Derivatives not designated as hedges	5,569		73		42		5,116		34		45
Total derivatives	$	8,971	$	119	$	271	$	8,488	$	66	$	209

Under the master arrangements with the respective counterparties to our derivative contracts, in certain circumstances and subject to applicable requirements, we are allowed to net settle transactions with a single net amount payable by one party to the other. However, we have elected to present the derivative assets and derivative liabilities on a gross basis on our Condensed Consolidated and Combined Statements of Financial Position and in the table above. The fair value of the derivatives contracts are recognized within All other current assets, All other assets, All other current liabilities, and All other liabilities in the Condensed Consolidated and Combined Statements of Financial Position based upon the contractual timing of settlements for these contracts.

As of March 31, 2023, the potential effect of rights of offset associated with the derivative contracts would be an offset to both assets and liabilities by $56 million.

The table below presents the pre-tax gains (losses) recognized in OCI associated with the Company’s cash flow and net investment hedges:


Pre-tax Gains (Losses) Recognized in OCI Related to Cash flow and Net Investment Hedges
	For the three months ended March 31
	2023		2022
Cash flow hedges	$	(17)	$	41
Net investment hedges	35		—

The table below presents the gains (losses) of our derivative financial instruments in the Condensed Consolidated and Combined Statements of Income:


Derivative Financial Instruments
	For the three months ended March 31, 2023								For the three months ended March 31, 2022
	Cost of products		Cost of services		Selling, general and administrative		Other (a)		Cost of products		Cost of services		Selling, general and administrative		Other (a)

Foreign currency exchange contracts	$	27	$	6	$	—	$	—	$	9	$	2	$	—	$	—
Effects of cash flow hedges	27		6		—		—		9		2		—		—
Cross-currency swaps	—		—		—		—		—		—		—		—
Effects of net investment hedges	—		—		—		—		—		—		—		—
Foreign currency exchange contracts	7		2		—		1		(1)		—		—		—
Embedded derivatives	—		—		—		(1)		—		—		—		3
Equity contracts	—		—		15		3		—		—		—		—
Commodity derivatives	—		—		—		(2)		—		—		—		10
Effect of derivatives not designated as hedges	$	7	$	2	$	15	$	1	$	(1)	$	—	$	—	$	13

(a) Amounts inclusive of Other income (expense) - net on the Condensed Consolidated and Combined Statements of Income.

FAIR VALUE MEASUREMENTS.

The following table represents financial assets and liabilities that are recorded and measured at fair value on a recurring basis:


Fair Value of Financial Assets and Liabilities
	March 31, 2023								December 31, 2022
	Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
Assets:
Investment securities	$	31	$	—	$	—	$	31	$	21	$	—	$	—	$	21
Derivatives	—		119		—		119		—		66		—		66
Liabilities:
Deferred compensation(a)	264		3		—		267		62		2		—		64
Derivatives	—		268		3		271		—		203		6		209
Contingent consideration	—		—		57		57		—		—		42		42

(a) Certain deferred compensation plans whose value is derived from market-based securities values were transferred from GE as part of the Spin-Off.

Contingent Consideration

The contingent consideration liabilities as of March 31, 2023 and December 31, 2022 were recorded in connection with business acquisitions. Changes in the Level 3 fair value measurement of contingent consideration were not material during the three months ended March 31, 2023 and 2022.

Fair Value of Other Financial Instruments

The estimated fair value of long-term debt (including the current portion) as of March 31, 2023 and December 31, 2022, was $10,819 million and $8,512 million compared to a carrying value (which includes a reduction for amortized debt issuance costs and discounts) of $10,239 million and $8,241 million, respectively. The fair value of our borrowings is determined based on observable and quoted prices and spreads of identical and comparable debt and benchmark securities and is considered Level 2 in the fair value hierarchy. See Note 8, “Borrowings” for further information.

Non-recurring Fair Value Measurements

Equity investments without readily determinable fair value as of March 31, 2023 and December 31, 2022, were $119 million and $117 million, respectively.

POSTRETIREMENT BENEFIT PLANS - Components of Net Periodic Expense (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Defined Benefit Plan Disclosure [Line Items]
Non-operating	$ (115)	$ (2)
Defined benefit plans
Defined Benefit Plan Disclosure [Line Items]
Service cost – Operating	14	5
Interest cost	292	4
Expected return on plan assets	(356)	(7)
Amortization of net loss (gain)	(29)	2
Amortization of prior service cost (credit)	(1)	(1)
Non-operating	(94)	(2)
Net periodic (income) expense	(80)	3
Other postretirement plans
Defined Benefit Plan Disclosure [Line Items]
Service cost – Operating	2	0
Interest cost	15	0
Expected return on plan assets	0	0
Amortization of net loss (gain)	(16)	0
Amortization of prior service cost (credit)	(22)	0
Non-operating	(23)	0
Net periodic (income) expense	$ (21)	$ 0

RESTRUCTURING AND OTHER ACTIVITIES (Tables)

3 Months Ended

Mar. 31, 2023

Restructuring and Related Activities [Abstract]

Schedule of Restructuring and Related Costs


Restructuring and Other Activities
	For the three months ended March 31
	2023		2022
Employee termination costs	$	10	$	9
Facility and other exit costs	1		3
Asset write-downs	1		—
Total restructuring and other activities	$	12	$	12

BORROWINGS - Schedule of Long-Term Borrowings (Details) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Principal debt issued	$ 10,283	$ 8,288
Less: Unamortized debt issuance costs and discounts	44	47
Less: Current portion of long-term borrowings	5	7
Long-term borrowings, net of current portion	$ 10,234	8,234
Senior notes \| 5.550% senior notes due November 15, 2024
Debt Instrument [Line Items]
Stated interest rate	5.55%
Principal debt issued	$ 1,000	1,000
Senior notes \| 5.600% senior notes due November 15, 2025
Debt Instrument [Line Items]
Stated interest rate	5.60%
Principal debt issued	$ 1,500	1,500
Senior notes \| 5.650% senior notes due November 15, 2027
Debt Instrument [Line Items]
Stated interest rate	5.65%
Principal debt issued	$ 1,750	1,750
Senior notes \| 5.857% senior notes due March 15, 2030
Debt Instrument [Line Items]
Stated interest rate	5.857%
Principal debt issued	$ 1,250	1,250
Senior notes \| 5.905% senior notes due November 22, 2032
Debt Instrument [Line Items]
Stated interest rate	5.905%
Principal debt issued	$ 1,750	1,750
Senior notes \| 6.377% senior notes due November 22, 2052
Debt Instrument [Line Items]
Stated interest rate	6.377%
Principal debt issued	$ 1,000	1,000
Line of credit \| Term Loan Facility
Debt Instrument [Line Items]
Principal debt issued	2,000	0
Other
Debt Instrument [Line Items]
Principal debt issued	$ 33	$ 38

REVENUE RECOGNITION

3 Months Ended

Mar. 31, 2023

Revenue from Contract with Customer [Abstract]

REVENUE RECOGNITION

Our revenues primarily consist of sales of products and services to customers. Products include equipment, imaging agents, software-related offerings, and upgrades. Services include contractual and stand-by preventative maintenance and corrective services, as well as related parts and labor, extended warranties, training, and other service-type offerings. The Company recognizes revenue from contracts with customers when the customer obtains control of the underlying products or services.


Contract and Other Deferred Assets
	As of
	March 31, 2023		December 31, 2022
Contract assets	$	593	$	584
Other deferred assets	390		405
Contract and other deferred assets	983		989
Non-current contract assets(a)	38		37
Non-current other deferred assets(a)	81		82
Total contract and other deferred assets	$	1,102	$	1,108

(a)Non-current contract and other deferred assets are recognized within All other assets in the Condensed Consolidated and Combined Statements of Financial Position.

Contract assets primarily reflect revenue recognized on contracts in excess of billings based on contractual terms. Contract assets are classified as current or non-current based on the amount of time expected to lapse until the Company’s right to consideration becomes unconditional. Other deferred assets consist of costs to obtain contracts, primarily commissions, other cost deferrals for shipped products, and deferred service, labor, and direct overhead costs.

CONTRACT LIABILITIES.

Contract liabilities primarily include customer advances and deposits received when orders are placed and billed in advance of completion of performance obligations. Contract liabilities are classified as current or non-current based on the periods over which remaining performance obligations are expected to be satisfied and fulfilled with our customers.

As of March 31, 2023 and December 31, 2022, contract liabilities were approximately $2,681 million and $2,526 million, respectively, of which the non-current portion of $650 million and $630 million, respectively, was recognized in All other liabilities in the Condensed Consolidated and Combined Statements of Financial Position. Contract liabilities increased by $155 million in 2023 primarily due to an increase in customer advances and deposits as a result of product orders growth relative to fulfillment and the normal annual service contract billing cycle. Revenue recognized related to the contract liabilities balance at the beginning of the year was approximately $759 million and $715 million for the three months ended March 31, 2023 and 2022, respectively.

REMAINING PERFORMANCE OBLIGATIONS.

Remaining performance obligations represent the estimated revenue expected from customer contracts that are partially or fully unperformed inclusive of amounts deferred in contract liabilities, excluding contracts, or portions thereof, that provide the customer with the ability to cancel or terminate without incurring a substantive penalty. As of March 31, 2023, the aggregate amount of the contracted revenues allocated to our unsatisfied (or partially unsatisfied) performance obligations was $14,490 million. We expect to recognize revenue as we satisfy our remaining performance obligations as follows: a) product-related remaining performance obligations of $4,966 million of which 99% is expected to be recognized within two years, and the remaining thereafter; and b) services-related remaining performance obligations of $9,524 million of which 67% and 97% is expected to be recognized within two years and five years, respectively, and the remaining thereafter.

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI https://asc.fasb.org/topic&trid=49130388

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

+ Details

FINANCING RECEIVABLES (Tables)

3 Months Ended

Mar. 31, 2023

Receivables [Abstract]

Schedule of Receivables


Current Receivables
	As of
	March 31, 2023		December 31, 2022
Current customer receivables(a)	$	3,150	$	3,112
Non-income based tax receivables	192		174
Other sundry receivables	122		100
Sundry receivables	314		274
Allowance for credit losses	(91)		(91)
Total current receivables – net	$	3,373	$	3,295

(a) Chargebacks, which are primarily related to our PDx business, are generally settled through issuance of credits, typically within one month of initial recognition, and are recorded as a reduction to current customer receivables. Balances related to chargebacks were $200 million and $157 million as of March 31, 2023 and December 31, 2022, respectively. The increase in chargebacks is primarily due to higher wholesaler product levels.


Long-Term Receivables
	As of
	March 31, 2023		December 31, 2022
Long-term customer receivables	$	71	$	80
Sundry receivables	71		57
Non-income based tax receivables	28		28
Supplier advances	11		11
Allowance for credit losses	(30)		(31)
Total long-term receivables – net(a)	$	151	$	145

(a) Long-term receivables are recognized within All other assets in the Condensed Consolidated and Combined Statements of Financial Position.


Financing Receivables
	As of
	March 31, 2023		December 31, 2022
Loans, net of deferred income	$	31	$	29
Investment in financing leases, net of deferred income	73		72
Allowance for credit losses	(4)		(4)
Current financing receivables – net(a)	100		97
Loans, net of deferred income	44		44
Investment in financing leases, net of deferred income	157		158
Allowance for credit losses	(5)		(6)
Non-current financing receivables – net(a)	$	196	$	196

(a) Current financing receivables and non-current financing receivables are recognized within All other current assets and All other assets, respectively, in the Condensed Consolidated and Combined Statements of Financial Position.

SHARE-BASED COMPENSATION - Summary of Share-Based Compensation Expense (Details) $ in Millions	3 Months Ended
	Mar. 31, 2023 USD ($)
Share-Based Payment Arrangement [Abstract]
Compensation expense (pre-tax)	$ 24
Income tax benefits	(8)
Compensation expense (after-tax)	$ 16

SHARE-BASED COMPENSATION - Narrative (Details) $ / shares in Units, shares in Thousands, $ in Millions	3 Months Ended
	Mar. 31, 2023 USD ($) $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares authorized for issuance	41,000
Stock options
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expiration period	10 years
Stock options \| Minimum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting period	3 years
Stock options \| Maximum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting period	3 years 6 months
Performance Shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Units outstanding (in shares)	1,271
Weighted average grant date fair value (in dollars per share) \| $ / shares	$ 85
Intrinsic value, outstanding \| $	$ 104
Weighted average remaining contractual term, outstanding	2 years

Condensed Consolidated and Combined Statements of Financial Position (Unaudited) (Parentheticals) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Allowance for credit losses	$ 91	$ 91
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, authorized (in shares)	1,000,000,000	1,000,000,000
Common stock, issued (in shares)	454,617,131	100
Common stock, outstanding (in shares)	454,617,131	100

COMMITMENTS, GUARANTEES, PRODUCT WARRANTIES, AND OTHER LOSS CONTINGENCIES

3 Months Ended

Mar. 31, 2023

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS, GUARANTEES, PRODUCT WARRANTIES, AND OTHER LOSS CONTINGENCIES

GUARANTEES.

The Company has off-balance sheet credit exposure through standby letters of credit, bank guarantees, bid bonds, and surety bonds. See Note 8, “Borrowings" for further information. In addition, GE has provided parent company guarantees in certain jurisdictions where we lack the legal structure to issue the requisite guarantees required on certain projects.

Following the Spin-Off, which was completed pursuant to a Separation and Distribution Agreement (the "Separation and Distribution Agreement"), the Company has remaining performance guarantees on behalf of GE. Under the Separation and Distribution Agreement, GE is obligated to use reasonable best efforts to replace the Company as the guarantor or terminate all such performance guarantees. Until such termination or replacement, in the event of non-fulfillment of contractual obligations by the relevant obligors, the Company could be obligated to make payments under the applicable instruments for which GE is obligated to reimburse and indemnify the Company. As of March 31, 2023 the Company’s maximum aggregate exposure, subject to GE reimbursement, is approximately $164 million.

PRODUCT WARRANTIES.

We provide warranty coverage to our customers as part of customary practices in the market to provide assurance that the products we sell comply with agreed-upon specifications. We provide estimated product warranty expenses when we sell the related products. Warranty accruals are estimates that are based on the best available information, mostly historical claims experience, therefore claims costs may differ from amounts provided. An analysis of changes in the liability for product warranties follows.


Product Warranties
	For the three months ended March 31
	2023		2022
Balance at beginning of period	$	193	$	161
Current-year provisions	49		55
Expenditures	(51)		(45)
Other changes	2		(1)
Balance at end of period	$	193	$	170

Product warranties are recognized within All other current liabilities in the Condensed Consolidated and Combined Statements of Financial Position.

LEGAL MATTERS.

In the normal course of our business, we are involved from time to time in various arbitrations; class actions; commercial, intellectual property, and product liability litigation; government investigations; investigations by competition/antitrust authorities; and other legal, regulatory, or governmental actions, including the significant matter described below that could have a material impact on our results of operations. In many proceedings, including the specific matter described below, it is inherently difficult to determine whether any loss is probable or even reasonably possible or to estimate the size or range of the possible loss, and accruals for legal matters are not recorded until a loss for a particular matter is considered probable and reasonably estimable. Given the nature of legal matters and the complexities involved, it is often difficult to predict and determine a meaningful estimate of loss or range of loss until we know, among other factors, the particular claims involved, the likelihood of success of our defenses to those claims, the damages or other relief sought, how discovery or other procedural considerations will affect the outcome, the settlement posture of other parties, and other factors that may have a material effect on the outcome. For such matters, unless otherwise specified, we do not believe it is possible to provide a meaningful estimate of loss at this time. Moreover, it is not uncommon for legal matters to be resolved over many years, during which time relevant developments and new information must be continuously evaluated.

Contracts with Iraqi Ministry of Health

In 2017, a number of U.S. Service members, civilians, and their families brought a complaint in the U.S. District Court for the District of Columbia (the “District Court”) against a number of pharmaceutical and medical device companies, including GE HealthCare and certain affiliates, alleging that the defendants violated the U.S. Anti-Terrorism Act. The complaint seeks monetary relief and alleges that the defendants provided funding for an Iraqi terrorist organization through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health. In July 2020, the District Court granted defendants’ motions to dismiss and dismissed all of the plaintiffs’ claims. In January 2022, a panel of the U.S. Court of Appeals for the District of Columbia Circuit reversed the District Court’s decision. In February 2022, the defendants requested review of the decision by all of the judges on the U.S. Court of Appeals for the District of Columbia Circuit (“the D.C. Circuit”). On February 2, 2023, the D.C. Circuit denied this request. On February 10, 2023, defendants filed a motion for a temporary, partial stay of further district court proceedings until the Supreme Court issues its decision in a separate case, Twitter, Inc. v. Taamneh, which also involves the U.S. Anti-Terrorism Act. On March 1, 2023, the District Court granted the motion for a temporary, partial stay. Defendants also plan to petition the Supreme Court to review the D.C. Circuit’s decision.

SUPPLEMENTAL FINANCIAL INFORMATION (Tables)

3 Months Ended

Mar. 31, 2023

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of Cash and Cash Equivalents


Cash, Cash Equivalents and Restricted Cash	As of
	March 31, 2023		December 31, 2022
Cash and cash equivalents	$	2,324	$	1,440
Short-term restricted cash	3		5
Total cash, cash equivalents, and restricted cash as presented on the Condensed Consolidated and Combined Statements of Financial Position	2,327		1,445
Long-term restricted cash(a)	7		6
Total cash, cash equivalents, and restricted cash as presented on the Condensed Consolidated and Combined Statements of Cash Flows	$	2,334	$	1,451

(a) Long-term restricted cash is recognized within All other assets in the Condensed Consolidated and Combined Statements of Financial Position.

Schedule of Restricted Cash and Cash Equivalents


Cash, Cash Equivalents and Restricted Cash	As of
	March 31, 2023		December 31, 2022
Cash and cash equivalents	$	2,324	$	1,440
Short-term restricted cash	3		5
Total cash, cash equivalents, and restricted cash as presented on the Condensed Consolidated and Combined Statements of Financial Position	2,327		1,445
Long-term restricted cash(a)	7		6
Total cash, cash equivalents, and restricted cash as presented on the Condensed Consolidated and Combined Statements of Cash Flows	$	2,334	$	1,451

(a) Long-term restricted cash is recognized within All other assets in the Condensed Consolidated and Combined Statements of Financial Position.

Schedule of Current Inventory


Inventories
	As of
	March 31, 2023		December 31, 2022
Raw materials	$	1,097	$	1,053
Work in process	107		91
Finished goods	1,052		1,011
Inventories(a)	$	2,256	$	2,155

(a) Certain inventory items are long-term in nature and therefore have been recognized within All other assets in the Condensed Consolidated and Combined Statements of Financial Position.

Schedule of Redeemable Noncontrolling Interest

The activity attributable to redeemable noncontrolling interests for the three months ended March 31, 2023 and 2022 is presented below.


Redeemable Noncontrolling Interests
	For the three months ended March 31
	2023		2022
Balance at beginning of period	$	230	$	220
Net income attributable to redeemable noncontrolling interests	10		9
Redemption value adjustments(a)	183		—
Exercise of redeemable noncontrolling interests(b)	(222)		—
Balance at end of period	$	201	$	229

(a) As of January 3, 2023, certain redeemable noncontrolling interests were probable of becoming redeemable due to the change of control that occurred upon consummation of the Spin-Off. These redeemable noncontrolling interests were remeasured to their current redemption value resulting in a redemption value adjustment of $183 million. The remeasurement was accounted for as a deemed preferred stock dividend of redeemable noncontrolling interest and recorded as an adjustment to retained earnings.

(b) In February 2023, the redeemable noncontrolling interest holder exercised its option redemption provision. The expected redemption payment of $222 million is expected to be made in the second quarter of 2023 and has been recognized within All other current liabilities.

Schedule of Other Income (Expense)


Other Income (Expense) – Net
	For the three months ended March 31
	2023		2022
Net interest and investment income (expense)	$	13	$	(2)
Equity method investment income	4		3
Change in fair value of assumed obligation	(13)		—
Other items, net(a)	4		25
Total other income (expense) – net	$	8	$	26

(a) Other items, net primarily consists of licensing and royalty income and gains and losses related to derivatives for the three months ended March 31, 2022.

BORROWINGS (Tables)

3 Months Ended

Mar. 31, 2023

Debt Disclosure [Abstract]

Schedule of Long-Term Borrowings


Long-Term Borrowings Composition
	As of
	March 31, 2023		December 31, 2022
5.550% senior notes due November 15, 2024	$	1,000	$	1,000
5.600% senior notes due November 15, 2025	1,500		1,500
5.650% senior notes due November 15, 2027	1,750		1,750
5.857% senior notes due March 15, 2030	1,250		1,250
5.905% senior notes due November 22, 2032	1,750		1,750
6.377% senior notes due November 22, 2052	1,000		1,000
Term Loan Facility	2,000		—
Other	33		38
Total principal debt issued	10,283		8,288
Less: Unamortized debt issuance costs and discounts	44		47
Less: Current portion of long-term borrowings	5		7
Long-term borrowings, net of current portion	$	10,234	$	8,234

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 55
-Paragraph 69B
-URI https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 55
-Paragraph 69E
-URI https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644

+ Details

POSTRETIREMENT BENEFIT PLANS

3 Months Ended

Mar. 31, 2023

Retirement Benefits [Abstract]

POSTRETIREMENT BENEFIT PLANS

PENSION BENEFITS AND RETIREE HEALTH AND LIFE BENEFITS SPONSORED BY GE, TRANSFERRED TO GE HEALTHCARE IN CONNECTION WITH THE SPIN-OFF.

Certain GE HealthCare employees were covered under various pension and retiree health and life plans sponsored by GE prior to the Spin-Off, including principal pension plans, other pension plans, and principal retiree benefit plans. A subset of these pension plans have been closed to new participants. For the three months ended March 31, 2022, relevant participation costs for these plans were allocated to the Company and recognized within the Condensed Combined Statement of Income. These included service costs for active employees in the U.S. GE Pension Plan, certain international pension plans, the U.S. GE Supplementary Pension Plan, and the U.S. retiree benefit plan. We did not record any liabilities associated with our participation in these plans in our Condensed Combined Statement of Financial Position as of December 31, 2022.

Expenses associated with our employees’ participation in the U.S. GE principal pension and principal retiree benefit plans, which represent the majority of related expense, were $24 million for the three months ended March 31, 2022. Expenses associated with our employees’ participation in GE’s non-U.S. based pension plans were $4 million for the three months ended March 31, 2022.

In connection with the Spin-Off, on January 1, 2023, these plans were separated and GE transferred certain liabilities and assets of these plans to GE HealthCare based upon measurements as of December 31, 2022. The amounts assumed by GE HealthCare on January 1, 2023, are shown in the tables below.


Accumulated Benefit Obligations and Unrecognized Gain
	As of January 1, 2023
	Defined benefit plans		Other postretirement plans		Total
Accumulated benefit obligations	$	21,696	$	1,210	$	22,906

Unrecognized gain to be recorded in AOCI	1,258		1,223		2,481


Net Benefit Liability
	As of January 1, 2023
	Defined benefit plans		Other postretirement plans		Total
Projected benefit obligations	$	21,743	$	1,210	$	22,953
Fair value of assets	18,908		—		18,908
Net liability	$	2,835	$	1,210	$	4,045

PENSION PLANS SPONSORED BY GE HEALTHCARE, INCLUDING THOSE TRANSFERRED BY GE.

As the pension plans were transferred by GE on January 1, 2023 there are no amounts included for these plans in the period ended March 31, 2022. Pension plans with pension assets or obligations less than $50 million and $20 million as of March 31, 2023 and 2022, respectively, are not included in the results below.


Components of Expense (Income)
	Defined benefit plans				Other postretirement plans

For the three months ended March 31	2023		2022		2023		2022
Service cost – Operating	$	14	$	5	$	2	$	—
Interest cost	292		4		15		—
Expected return on plan assets	(356)		(7)		—		—
Amortization of net loss (gain)	(29)		2		(16)		—
Amortization of prior service cost (credit)	(1)		(1)		(22)		—

Non-operating	$	(94)	$	(2)	$	(23)	$	—
Net periodic (income) expense	$	(80)	$	3	$	(21)	$	—

For the three months ended March 31, 2023, the Company made contributions for benefit payments totaling $48 million to the pension plans and $43 million to its postretirement plans. For the remainder of 2023, the Company expects to make future benefit payments of approximately $255 million to our defined benefit pension and postretirement plans for benefit payments. The Company does not have a required minimum cash pension contribution obligation for its U.S. plans in 2023. Future contributions will depend on market conditions, interest rates, and other factors.

Prior to the Spin-Off, we disclosed postretirement plans with assets or obligations that exceeded $20 million. As a result of the transferred liabilities and assets to GE HealthCare on January 1, 2023, we now present postretirement plans with assets or obligations that exceed $50 million. For the year, the Company expects to contribute approximately $11 million to postretirement plans that are no longer disclosed.

Defined Contribution Plan

As a result of the Spin-Off, GE HealthCare established a defined contribution plan for its eligible U.S. employees that was largely consistent with the plan they participated in while GE HealthCare operated as a business of GE. Expenses associated with our employees’ participation in GE HealthCare’s defined contribution plan in 2023 and GE’s defined contribution plan in 2022 represent the employer matching contributions for GE HealthCare employees and were $33 million and $31 million for the three months ended March 31, 2023 and 2022, respectively.

- Definition

The entire disclosure for retirement benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 55
-Paragraph 17
-URI https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section S99
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(i)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (o)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (p)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 70
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-URI https://asc.fasb.org/topic&trid=2235017

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 60
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(iv)(03)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (q)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (r)(1)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(iii)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (l)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (r)(2)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

+ Details

INCOME TAXES (Details) - USD ($) $ in Millions	3 Months Ended
INCOME TAXES (Details) - USD ($) $ in Millions	Mar. 31, 2023	Mar. 31, 2022	Jan. 03, 2023
Income Tax Disclosure [Abstract]
Effective income tax rate	29.90%	24.60%
Deferred tax liabilities, undistributed foreign earnings	$ 30
Deferred tax assets, net			$ 3,099
Deferred tax assets, pension and post retirement benefits			$ 964

SEGMENT INFORMATION

3 Months Ended

Mar. 31, 2023

Segment Reporting [Abstract]

SEGMENT INFORMATION

GE HealthCare’s operations are organized and managed through four reportable segments: Imaging, Ultrasound, Patient Care Solutions (“PCS”), and Pharmaceutical Diagnostics (“PDx”). These segments have been identified based on the nature of the products sold and how the Company manages its operations. We have not aggregated any of our operating segments to form reportable segments. A description of our reportable segments has been provided in the “Business” section of our Annual Report on Form 10-K for the year ended December 31, 2022.

The performance of these segments is principally measured based on Total revenues and an earnings metric defined as “Segment EBIT.” Segment EBIT is calculated as Income from continuing operations less the following: Benefit (provision) for income taxes, Interest and other financial charges – net, Non-operating benefit (income) costs, restructuring costs, acquisition and disposition-related benefits (charges), gains and losses on business dispositions, Spin-Off and separation costs, amortization of acquisition-related intangible assets, and investment revaluation gains and losses.


Total Revenues by Segment
	For the three months ended March 31

	2023		2022
Imaging:
Radiology	$	2,088	$	1,918
Interventional Guidance	408		393
Total Imaging	2,496		2,311
Total Ultrasound	859		815
PCS:
Monitoring Solutions	552		521
Life Support Solutions	229		195
Total PCS	781		716
Total PDx	558		484
Other(a)	13		17
Total revenues	$	4,707	$	4,343

(a) Financial information not presented within the reportable segments, shown within the Other category, represents the HealthCare Financial Services (“HFS”) business which does not meet the definition of an operating segment.


Segment EBIT
	For the three months ended March 31
	2023		2022
Segment EBIT
Imaging	$	191	$	206
Ultrasound	207		192
PCS	109		65
PDx	155		138
Other(a)	2		(2)
	664		599
Restructuring costs	(12)		(12)
Acquisition and disposition-related benefits (charges)	(1)		(15)
Gain (loss) of business dispositions and divestments	—		3
Spin-Off and separation costs	(58)		—
Amortization of acquisition-related intangible assets	(31)		(33)
Investment revaluation gain (loss)	5		(8)
Interest and other financial charges – net	(136)		(4)
Non-operating benefit income (costs)	115		2
Income from continuing operations before income taxes	$	546	$	533

(a)Financial information not presented within the reportable segments, shown within the Other category, represents the HFS business and certain other investments which do not meet the definition of an operating segment.

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-URI https://asc.fasb.org/topic&trid=2134510

+ Details

Condensed Consolidated and Combined Statements of Cash Flows (Unaudited) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Cash flows - operating activities
Net income	$ 383	$ 402
Adjustments to reconcile Net income to Cash from (used for) operating activities
Depreciation and amortization of property, plant, and equipment	61	56
Amortization of acquisition-related intangible assets	96	103
Net periodic postretirement benefit plan (income) expense	(101)	3
Postretirement plan contributions	(91)	(6)
Provision for income taxes	163	131
Share-based compensation	24	19
Cash paid during the year for income taxes	(102)	(203)
Cash paid during the year for interest	(42)	0
Changes in operating assets and liabilities, excluding the effects of acquisitions and dispositions:
Receivables	(22)	(139)
Due from related parties	5	(5)
Inventories	(122)	(244)
Contract and other deferred assets	12	(34)
Accounts payable	87	319
Due to related parties	6	16
Contract liabilities	119	77
All other operating activities	(8)	(27)
Cash from (used for) operating activities	468	468
Cash flows – investing activities
Additions to property, plant, and equipment	(143)	(100)
Dispositions of property, plant, and equipment	0	3
Purchases of businesses, net of cash acquired	(127)	0
All other investing activities	4	(3)
Cash from (used for) investing activities	(266)	(100)
Cash flows – financing activities
Net increase (decrease) in borrowings (maturities of 90 days or less)	(9)	2
Newly issued debt, net of debt issuance costs (maturities longer than 90 days)	2,000	0
Repayments and other reductions (maturities longer than 90 days)	(6)	(1)
Net transfers (to) from GE	(1,317)	(391)
All other financing activities	5	(30)
Cash from (used for) financing activities	673	(420)
Effect of foreign currency rate changes on cash, cash equivalents, and restricted cash	8	(3)
Increase (decrease) in cash, cash equivalents, and restricted cash	883	(55)
Cash, cash equivalents, and restricted cash at beginning of year	1,451	561
Cash, cash equivalents, and restricted cash as of March 31	$ 2,334	$ 506

EARNINGS PER SHARE (Tables)

3 Months Ended

Mar. 31, 2023

Earnings Per Share [Abstract]

Schedule of Earnings per Share


Earnings Per Share
	For the three months ended March 31
(In millions, except per share amounts)	2023		2022
Numerator:
Net income	$	383	$	402
Net (income) attributable to noncontrolling interests	(11)		(13)
Net income attributable to GE HealthCare	372		389
Deemed preferred stock dividend of redeemable noncontrolling interest	(183)		—

Net income attributable to GE HealthCare common stockholders	$	189	$	389
Denominator:
Basic weighted-average shares outstanding	454		454
Dilutive effect of common stock equivalents	3		—
Diluted weighted-average shares outstanding	457		454
Basic Earnings Per Share	$	0.42	$	0.86



Diluted Earnings Per Share	$	0.41	$	0.86



Antidilutive securities(a)	4		—

(a) Diluted EPS excludes certain shares issuable under stock based compensation plans because the effect would have been antidilutive.

RESTRUCTURING AND OTHER ACTIVITIES - Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Restructuring and Related Activities [Abstract]
Restructuring expenses	$ 12	$ 12
Expected additional restructuring expense	71
Accrual adjustment	31
Restructuring liabilities	$ 99		$ 75

POSTRETIREMENT BENEFIT PLANS (Tables)

3 Months Ended

Mar. 31, 2023

Retirement Benefits [Abstract]

Schedule of Defined Benefit Plans

The amounts assumed by GE HealthCare on January 1, 2023, are shown in the tables below.


Accumulated Benefit Obligations and Unrecognized Gain
	As of January 1, 2023
	Defined benefit plans		Other postretirement plans		Total
Accumulated benefit obligations	$	21,696	$	1,210	$	22,906

Unrecognized gain to be recorded in AOCI	1,258		1,223		2,481


Net Benefit Liability
	As of January 1, 2023
	Defined benefit plans		Other postretirement plans		Total
Projected benefit obligations	$	21,743	$	1,210	$	22,953
Fair value of assets	18,908		—		18,908
Net liability	$	2,835	$	1,210	$	4,045

Components of Net Periodic Expense


Components of Expense (Income)
	Defined benefit plans				Other postretirement plans

For the three months ended March 31	2023		2022		2023		2022
Service cost – Operating	$	14	$	5	$	2	$	—
Interest cost	292		4		15		—
Expected return on plan assets	(356)		(7)		—		—
Amortization of net loss (gain)	(29)		2		(16)		—
Amortization of prior service cost (credit)	(1)		(1)		(22)		—

Non-operating	$	(94)	$	(2)	$	(23)	$	—
Net periodic (income) expense	$	(80)	$	3	$	(21)	$	—

Condensed Consolidated and Combined Statements of Changes in Equity (Unaudited) - USD ($) $ in Millions	Total	Common stock	Additional paid-in capital	Retained earnings	Net parent investment	Accumulated other comprehensive income (loss) – net	Equity attributable to noncontrolling interests
Equity, beginning balance (in shares) at Dec. 31, 2021		0
Equity, beginning balance at Dec. 31, 2021	$ 16,676	$ 0	$ 0	$ 0	$ 17,692	$ (1,037)	$ 21
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income attributable to GE HealthCare	389				389
Currency translation adjustments – net of taxes	(153)					(153)
Benefit plans – net of taxes	(5)					(5)
Cash flow hedges – net of taxes	24					24
Transfers (to) from GE	(353)				(353)
Changes in equity attributable to noncontrolling interests	0
Equity, ending balance (in shares) at Mar. 31, 2022		0
Equity, ending balance at Mar. 31, 2022	$ 16,578	$ 0	0	0	17,728	(1,171)	21
Equity, beginning balance (in shares) at Dec. 31, 2022	100	0
Equity, beginning balance at Dec. 31, 2022	$ 9,362	$ 0	0	0	11,235	(1,878)	5
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net transfers from Parent, including Spin-Off-related adjustments	(2,834)				(4,833)	2,000	(1)
Issuance of common stock in connection with the Spin-Off and reclassification of net parent investment (in shares)		454,000,000
Issuance of common stock in connection with the Spin-Off and reclassification of net parent investment	0	$ 5	6,397		(6,402)
Issuance of common stock in connection with employee stock plans (in shares)		1,000,000
Issuance of common stock in connection with employee stock plans	4		4
Net income attributable to GE HealthCare	372			372
Currency translation adjustments – net of taxes	57					57
Benefit plans – net of taxes	(65)					(65)
Cash flow hedges – net of taxes	(39)					(39)
Changes in equity attributable to noncontrolling interests	2						2
Share-based compensation expense	24		24
Changes in equity due to redemption value adjustments on redeemable noncontrolling interests	$ (187)			(187)
Equity, ending balance (in shares) at Mar. 31, 2023	454,617,131	455,000,000
Equity, ending balance at Mar. 31, 2023	$ 6,696	$ 5	$ 6,425	$ 185	$ 0	$ 75	$ 6

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Schedule of Derivative Pre-tax Gains (Losses) Recognized in OCI (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Cash flow hedges	$ (17)	$ 41
Net investment hedges	$ 35	$ 0

SEGMENT INFORMATION - Schedule of Segment Reporting Information (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Segment Reporting Information [Line Items]
Revenue	$ 4,707	$ 4,343
Segment EBIT	664	599
Restructuring costs	(12)	(12)
Acquisition and disposition-related benefits (charges)	(1)	(15)
Gain (loss) of business dispositions and divestments	0	3
Spin-Off and separation costs	(58)	0
Amortization of acquisition-related intangible assets	(31)	(33)
Investment revaluation gain (loss)	5	(8)
Interest and other financial charges – net	(136)	(4)
Non-operating benefit (income) costs	115	2
Income from continuing operations before income taxes	546	533
Operating segments \| Imaging
Segment Reporting Information [Line Items]
Revenue	2,496	2,311
Segment EBIT	191	206
Operating segments \| Imaging \| Radiology
Segment Reporting Information [Line Items]
Revenue	2,088	1,918
Operating segments \| Imaging \| Interventional Guidance
Segment Reporting Information [Line Items]
Revenue	408	393
Operating segments \| Ultrasound
Segment Reporting Information [Line Items]
Revenue	859	815
Segment EBIT	207	192
Operating segments \| PCS
Segment Reporting Information [Line Items]
Revenue	781	716
Segment EBIT	109	65
Operating segments \| PCS \| Monitoring Solutions
Segment Reporting Information [Line Items]
Revenue	552	521
Operating segments \| PCS \| Life Support Solutions
Segment Reporting Information [Line Items]
Revenue	229	195
Operating segments \| PDx
Segment Reporting Information [Line Items]
Revenue	558	484
Segment EBIT	155	138
Other
Segment Reporting Information [Line Items]
Revenue	13	17
Segment EBIT	$ 2	$ (2)

SEGMENT INFORMATION (Tables)

3 Months Ended

Mar. 31, 2023

Segment Reporting [Abstract]

Schedule of Segment Reporting Information


Total Revenues by Segment
	For the three months ended March 31

	2023		2022
Imaging:
Radiology	$	2,088	$	1,918
Interventional Guidance	408		393
Total Imaging	2,496		2,311
Total Ultrasound	859		815
PCS:
Monitoring Solutions	552		521
Life Support Solutions	229		195
Total PCS	781		716
Total PDx	558		484
Other(a)	13		17
Total revenues	$	4,707	$	4,343


Segment EBIT
	For the three months ended March 31
	2023		2022
Segment EBIT
Imaging	$	191	$	206
Ultrasound	207		192
PCS	109		65
PDx	155		138
Other(a)	2		(2)
	664		599
Restructuring costs	(12)		(12)
Acquisition and disposition-related benefits (charges)	(1)		(15)
Gain (loss) of business dispositions and divestments	—		3
Spin-Off and separation costs	(58)		—
Amortization of acquisition-related intangible assets	(31)		(33)
Investment revaluation gain (loss)	5		(8)
Interest and other financial charges – net	(136)		(4)
Non-operating benefit income (costs)	115		2
Income from continuing operations before income taxes	$	546	$	533

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) – NET (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Equity, beginning balance	$ 9,362	$ 16,676
Other comprehensive income (loss) before reclass – net of taxes	59	(123)
Unrecognized gain transferred from GE pension – net of taxes	1,972
Reclass from AOCI – net of taxes	(78)	(11)
Equity, ending balance	6,696	16,578
Accumulated other comprehensive income (loss) – net
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Equity, beginning balance	(1,878)	(1,037)
Equity, ending balance	75	(1,171)
Currency translation adjustments
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Equity, beginning balance	(1,845)	(969)
Other comprehensive income (loss) before reclass – net of taxes	85	(153)
Unrecognized gain transferred from GE pension – net of taxes	0
Reclass from AOCI – net of taxes	0	0
Equity, ending balance	(1,760)	(1,122)
Other comprehensive income (loss) before reclass, tax	(11)	(2)
Unrecognized gain transferred from GE pension, tax	0
Reclass from AOCI, tax	0	0
Benefit plans
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Equity, beginning balance	(42)	(100)
Other comprehensive income (loss) before reclass – net of taxes	(13)	(5)
Unrecognized gain transferred from GE pension – net of taxes	1,972
Reclass from AOCI – net of taxes	(52)	0
Equity, ending balance	1,865	(105)
Other comprehensive income (loss) before reclass, tax	2	(9)
Unrecognized gain transferred from GE pension, tax	(509)
Reclass from AOCI, tax	16	0
Cash flow hedges
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Equity, beginning balance	9	32
Other comprehensive income (loss) before reclass – net of taxes	(13)	35
Unrecognized gain transferred from GE pension – net of taxes	0
Reclass from AOCI – net of taxes	(26)	(11)
Equity, ending balance	(30)	56
Other comprehensive income (loss) before reclass, tax	4	(6)
Unrecognized gain transferred from GE pension, tax	0
Reclass from AOCI, tax	$ 7	$ 0

SHARE-BASED COMPENSATION - Summary of Share-Based Compensation Activity (Details) $ / shares in Units, shares in Thousands, $ in Millions	3 Months Ended
	Mar. 31, 2023 USD ($) $ / shares shares	Mar. 31, 2023 USD ($) $ / shares shares
Stock options, shares
Outstanding at beginning of period (in shares) \| shares	3,738
Granted (in shares) \| shares	2,037
Exercised (in shares) \| shares	(326)
Forfeited (in shares) \| shares	(3)
Expired (in shares) \| shares	(5)
Outstanding at end of period (in shares) \| shares	5,441	5,441
Exercisable (in shares) \| shares	3,182	3,182
Expected to vest (in shares) \| shares	1,681	1,681
Stock options, weighted average exercise price
Outstanding at beginning of period (in dollars per share) \| $ / shares	$ 90
Granted (in dollars per share) \| $ / shares	71
Exercised (in dollars per share) \| $ / shares	56
Forfeited (in dollars per share) \| $ / shares	68
Expired (in dollars per share) \| $ / shares	143
Outstanding at end of period (in dollars per share) \| $ / shares	85	$ 85
Exercisable (in dollars per share) \| $ / shares	94	94
Expected to vest (in dollars per share) \| $ / shares	$ 71	$ 71
Stock options, weighted average contractual term (in years)
Stock options, weighted average remaining contractual term, outstanding	6 years 7 months 6 days
Stock options, weighted average remaining contractual term, exercisable	4 years 3 months 18 days
Stock options, weighted average remaining contractual term, expected to vest	9 years 8 months 12 days
Stock options, intrinsic value
Stock options, intrinsic value, outstanding \| $	$ 57	$ 57
Stock options, intrinsic value, exercisable \| $	33	33
Stock options, intrinsic value, expected to vest \| $	$ 18	$ 18
RSUs
RSUs, shares
Outstanding at beginning of period (in shares) \| shares	3,551
Granted (in shares) \| shares	1,612
Vested (in shares) \| shares	(558)
Forfeited (in shares) \| shares	(52)
Outstanding at end of period (in shares) \| shares	4,553	4,553
Expected to vest (in shares) \| shares	3,817	3,817
RSUs, weighted average grant date fair value
Outstanding at beginning of period (in dollars per share) \| $ / shares	$ 58
Granted (in dollars per share) \| $ / shares	72	$ 72
Vested (in dollars per share) \| $ / shares	70
Forfeited (in dollars per share) \| $ / shares	63
Outstanding at end of period (in dollars per share) \| $ / shares	63	63
Expected to vest (in dollars per share) \| $ / shares	$ 54	$ 54
RSUs, weighted average contractual term (in years)
Weighted average remaining contractual term, outstanding	2 years
Weighted average remaining contractual term, expected to vest	2 years
RSUs, intrinsic value
Intrinsic value, outstanding \| $	$ 374	$ 374
Intrinsic value, expected to vest \| $	$ 313	$ 313

RELATED PARTIES (Tables)

3 Months Ended

Mar. 31, 2023

Schedule of Related Party Transactions


Corporate Allocations from GE
	March 31, 2022
Costs for centralized services(a)	$	13
Costs associated with employee medical insurance(b)	30
Costs for corporate and shared services(c)	116

(a) Costs for centralized services such as public relations, treasury and cash management, and other services were recognized within SG&A in the Condensed Combined Statement of Income.

(c) Costs for corporate and shared services such as information technology, finance and other services were primarily recognized in SG&A and R&D in the Condensed Combined Statement of Income.

SUPPLEMENTAL FINANCIAL INFORMATION - Schedule of Redeemable Noncontrolling Interest (Details) - USD ($) $ in Millions		3 Months Ended
	Jan. 03, 2023	Jun. 30, 2023	Mar. 31, 2023	Mar. 31, 2022
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]
Balance at beginning of period		$ 201	$ 230	$ 220
Net income attributable to redeemable noncontrolling interests			10	9
Redemption value adjustments	$ 183		183	0
Exercise of redeemable noncontrolling interests			(222)	0
Balance at end of period			$ 201	$ 229
Subsequent event \| Forecast
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]
Noncontrolling interest redemption payment		$ 222

RELATED PARTIES - Schedule of Related Party Transactions (Details) - GE, before spin-off $ in Millions	3 Months Ended
	Mar. 31, 2022 USD ($)
Costs for centralized services
Related Party Transaction [Line Items]
Transaction amount	$ 13
Costs associated with employee medical insurance
Related Party Transaction [Line Items]
Transaction amount	30
Costs for corporate and shared services
Related Party Transaction [Line Items]
Transaction amount	$ 116

REVENUE RECOGNITION (Tables)

3 Months Ended

Mar. 31, 2023

Revenue from Contract with Customer [Abstract]

Summary of Contract and Other Deferred Assets


Contract and Other Deferred Assets
	As of
	March 31, 2023		December 31, 2022
Contract assets	$	593	$	584
Other deferred assets	390		405
Contract and other deferred assets	983		989
Non-current contract assets(a)	38		37
Non-current other deferred assets(a)	81		82
Total contract and other deferred assets	$	1,102	$	1,108

(a)Non-current contract and other deferred assets are recognized within All other assets in the Condensed Consolidated and Combined Statements of Financial Position.

FINANCING RECEIVABLES

3 Months Ended

Mar. 31, 2023

Receivables [Abstract]

FINANCING RECEIVABLES


Financing Receivables
	As of
	March 31, 2023		December 31, 2022
Loans, net of deferred income	$	31	$	29
Investment in financing leases, net of deferred income	73		72
Allowance for credit losses	(4)		(4)
Current financing receivables – net(a)	100		97
Loans, net of deferred income	44		44
Investment in financing leases, net of deferred income	157		158
Allowance for credit losses	(5)		(6)
Non-current financing receivables – net(a)	$	196	$	196

As of March 31, 2023, 6%, 4%, and 5% of financing receivables were over 30 days past due, over 90 days past due, and on nonaccrual, respectively, with the majority of nonaccrual financing receivables secured by collateral. As of December 31, 2022, 7%, 6%, and 6% of financing receivables were over 30 days past due, over 90 days past due, and on nonaccrual, respectively, with the majority of nonaccrual financing receivables secured by collateral.

RECEIVABLES - Long-Term Receivables (Details) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022
Receivables [Abstract]
Long-term customer receivables	$ 71	$ 80
Sundry receivables	71	57
Non-income based tax receivables	28	28
Supplier advances	11	11
Allowance for credit losses	(30)	(31)
Total long-term receivables – net	$ 151	$ 145

COMMITMENTS, GUARANTEES, PRODUCT WARRANTIES, AND OTHER LOSS CONTINGENCIES - Schedule of Product Warranties (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward]
Balance at beginning of period	$ 193	$ 161
Current-year provisions	49	55
Expenditures	(51)	(45)
Other changes	2	(1)
Balance at end of period	$ 193	$ 170

SUPPLEMENTAL FINANCIAL INFORMATION - Schedule of Inventory (Details) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Raw materials	$ 1,097	$ 1,053
Work in process	107	91
Finished goods	1,052	1,011
Inventories	$ 2,256	$ 2,155

RESTRUCTURING AND OTHER ACTIVITIES - Schedule of Restructuring and Related Costs (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Restructuring and Related Activities [Abstract]
Employee termination costs	$ 10	$ 9
Facility and other exit costs	1	3
Asset write-downs	1	0
Total restructuring and other activities	$ 12	$ 12

ACQUISITIONS, GOODWILL, AND OTHER INTANGIBLE ASSETS

3 Months Ended

Mar. 31, 2023

Goodwill and Intangible Assets Disclosure [Abstract]

ACQUISITIONS, GOODWILL, AND OTHER INTANGIBLE ASSETS

ACQUISITIONS.

On February 17, 2023, the Company acquired 100% of the stock of Caption Health, Inc. (“Caption Health”) for $127 million of upfront payment, $10 million future holdback payment and potential earn-out payments valued at $13 million based primarily on various milestones and sales targets. The preliminary purchase price allocation resulted in goodwill of $105 million, intangible assets of $60 million, and deferred tax liabilities of $14 million. The goodwill associated with the acquired business is non-deductible for tax purposes and is reported in the Ultrasound segment. Caption Health is an artificial intelligence (“AI”) company whose technology expands access to AI-guided ultrasound screening for novice users.

See Note 12, “Financial Instruments and Fair Value Measurements” for further information about the fair value measurement of contingent consideration.


Goodwill
	Balance as of December 31, 2022		Acquisitions		Foreign exchange and other		Balance as of March 31, 2023
Imaging	$	4,409	$	—	$	4	$	4,413
Ultrasound	3,835		105		1		3,941
PCS	2,036		—		1		2,037
PDx	2,533		—		—		2,533
Total Goodwill	$	12,813	$	105	$	6	$	12,924

We assess the possibility that a reporting unit’s fair value has been reduced below its carrying amount due to the occurrence of events or circumstances between annual impairment testing dates. We did not identify any reporting units that required an interim impairment test since the last annual impairment testing date.

Substantially all other intangible assets are subject to amortization. Intangible assets decreased during the three months ended March 31, 2023, primarily as a result of amortization, partially offset by $60 million of additions related to the acquisition of Caption Health. Amortization expense was $96 million and $103 million for the three months ended March 31, 2023 and 2022, respectively.

ACQUISITIONS, GOODWILL, AND OTHER INTANGIBLE ASSETS

ACQUISITIONS.

See Note 12, “Financial Instruments and Fair Value Measurements” for further information about the fair value measurement of contingent consideration.


Goodwill
	Balance as of December 31, 2022		Acquisitions		Foreign exchange and other		Balance as of March 31, 2023
Imaging	$	4,409	$	—	$	4	$	4,413
Ultrasound	3,835		105		1		3,941
PCS	2,036		—		1		2,037
PDx	2,533		—		—		2,533
Total Goodwill	$	12,813	$	105	$	6	$	12,924

RECEIVABLES

3 Months Ended

Mar. 31, 2023

Receivables [Abstract]

RECEIVABLES


Current Receivables
	As of
	March 31, 2023		December 31, 2022
Current customer receivables(a)	$	3,150	$	3,112
Non-income based tax receivables	192		174
Other sundry receivables	122		100
Sundry receivables	314		274
Allowance for credit losses	(91)		(91)
Total current receivables – net	$	3,373	$	3,295


Long-Term Receivables
	As of
	March 31, 2023		December 31, 2022
Long-term customer receivables	$	71	$	80
Sundry receivables	71		57
Non-income based tax receivables	28		28
Supplier advances	11		11
Allowance for credit losses	(30)		(31)
Total long-term receivables – net(a)	$	151	$	145

(a) Long-term receivables are recognized within All other assets in the Condensed Consolidated and Combined Statements of Financial Position.

Cover - shares	3 Months Ended
Cover - shares	Mar. 31, 2023	Apr. 18, 2023
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2023
Document Transition Report	false
Entity File Number	001-41528
Entity Registrant Name	GE HEALTHCARE TECHNOLOGIES INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	88-2515116
Entity Address, Address Line One	500 W. Monroe Street
Entity Address, City or Town	Chicago
Entity Address, State or Province	IL
Entity Address, Postal Zip Code	60661
City Area Code	833
Local Phone Number	735-1139
Title of 12(b) Security	Common stock, par value $0.01 per share
Trading Symbol	GEHC
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		454,677,236
Amendment Flag	false
Entity Central Index Key	0001932393
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31

SHARE-BASED COMPENSATION - Summary of Weighted Average Grant Date Fair Value (Details) - $ / shares	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted-average grant date fair value of stock options (in dollars per share)		$ 25
RSUs
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted-average grant date fair value (in dollars per share)	$ 72	72
PSUs
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted-average grant date fair value (in dollars per share)		$ 84

SUPPLEMENTAL FINANCIAL INFORMATION - Schedule of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022	Mar. 31, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash and cash equivalents	$ 2,324	$ 1,440
Short-term restricted cash	3	5
Total cash, cash equivalents, and restricted cash as presented on the Condensed Consolidated and Combined Statements of Financial Position	2,327	1,445
Long-term restricted cash	7	6
Total cash, cash equivalents, and restricted cash as presented on the Condensed Consolidated and Combined Statements of Cash Flows	$ 2,334	$ 1,451	$ 506	$ 561

FINANCING RECEIVABLES - Schedule of Financing Receivable (Details) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022
Accounts, Notes, Loans and Financing Receivable [Line Items]
Allowance for credit losses	$ (4)	$ (4)
Current financing receivables, net	100	97
Allowance for credit losses	(5)	(6)
Non-current financing receivables, net	196	196
Loans, net of deferred income
Accounts, Notes, Loans and Financing Receivable [Line Items]
Current financing receivables, gross	31	29
Non-current financing receivables, gross	44	44
Investment in financing leases, net of deferred income
Accounts, Notes, Loans and Financing Receivable [Line Items]
Current financing receivables, gross	73	72
Non-current financing receivables, gross	$ 157	$ 158

PROPERTY, PLANT, AND EQUIPMENT AND OPERATING LEASES - Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Operating lease liability	$ 341		$ 347
Operating lease expense	$ 56	$ 56

SHARE-BASED COMPENSATION - Schedule of Stock Options Valuation Assumptions (Details) - Stock options	3 Months Ended
	Mar. 31, 2023 $ / shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Risk free rate	3.60%
Dividend yield	0.00%
Expected volatility	26.50%
Expected term (in years)	6 years 3 months 18 days
Strike price (in dollars per share)	$ 71

Condensed Consolidated and Combined Statements of Comprehensive Income (Unaudited) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Statement of Comprehensive Income [Abstract]
Net income attributable to GE HealthCare	$ 372	$ 389
Net (income) attributable to noncontrolling interests	11	13
Net income	383	402
Other comprehensive income (loss):
Currency translation adjustments – net of taxes	57	(153)
Benefit plans – net of taxes	(65)	(5)
Cash flow hedges – net of taxes	(39)	24
Other comprehensive income (loss)	(47)	(134)
Comprehensive income	336	268
Comprehensive (income) attributable to noncontrolling interests	(11)	(13)
Comprehensive income attributable to GE HealthCare	$ 325	$ 255

COMMITMENTS, GUARANTEES, PRODUCT WARRANTIES, AND OTHER LOSS CONTINGENCIES - Narrative (Details) $ in Millions	Mar. 31, 2023 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Guarantor obligations, maximum exposure	$ 164

RECEIVABLES (Tables)

3 Months Ended

Mar. 31, 2023

Receivables [Abstract]

Schedule of Receivables


Current Receivables
	As of
	March 31, 2023		December 31, 2022
Current customer receivables(a)	$	3,150	$	3,112
Non-income based tax receivables	192		174
Other sundry receivables	122		100
Sundry receivables	314		274
Allowance for credit losses	(91)		(91)
Total current receivables – net	$	3,373	$	3,295


Long-Term Receivables
	As of
	March 31, 2023		December 31, 2022
Long-term customer receivables	$	71	$	80
Sundry receivables	71		57
Non-income based tax receivables	28		28
Supplier advances	11		11
Allowance for credit losses	(30)		(31)
Total long-term receivables – net(a)	$	151	$	145

(a) Long-term receivables are recognized within All other assets in the Condensed Consolidated and Combined Statements of Financial Position.


Financing Receivables
	As of
	March 31, 2023		December 31, 2022
Loans, net of deferred income	$	31	$	29
Investment in financing leases, net of deferred income	73		72
Allowance for credit losses	(4)		(4)
Current financing receivables – net(a)	100		97
Loans, net of deferred income	44		44
Investment in financing leases, net of deferred income	157		158
Allowance for credit losses	(5)		(6)
Non-current financing receivables – net(a)	$	196	$	196

SHARE-BASED COMPENSATION - Summary of Other Share-Based Compensation Data (Details) $ in Millions	3 Months Ended
	Mar. 31, 2023 USD ($)
Share-Based Payment Arrangement [Abstract]
Unrecognized compensation expense (amortized over a weighted average period of 2.0 years)	$ 212
Cash received from stock options exercised	18
Intrinsic value of stock options exercised and RSU/PSUs vested	$ 48
Weighted average period of recognition	2 years

SUPPLEMENTAL FINANCIAL INFORMATION

3 Months Ended

Mar. 31, 2023

Organization, Consolidation and Presentation of Financial Statements [Abstract]

SUPPLEMENTAL FINANCIAL INFORMATION


Cash, Cash Equivalents and Restricted Cash	As of
	March 31, 2023		December 31, 2022
Cash and cash equivalents	$	2,324	$	1,440
Short-term restricted cash	3		5
Total cash, cash equivalents, and restricted cash as presented on the Condensed Consolidated and Combined Statements of Financial Position	2,327		1,445
Long-term restricted cash(a)	7		6
Total cash, cash equivalents, and restricted cash as presented on the Condensed Consolidated and Combined Statements of Cash Flows	$	2,334	$	1,451

(a) Long-term restricted cash is recognized within All other assets in the Condensed Consolidated and Combined Statements of Financial Position.


Inventories
	As of
	March 31, 2023		December 31, 2022
Raw materials	$	1,097	$	1,053
Work in process	107		91
Finished goods	1,052		1,011
Inventories(a)	$	2,256	$	2,155

(a) Certain inventory items are long-term in nature and therefore have been recognized within All other assets in the Condensed Consolidated and Combined Statements of Financial Position.

ALL OTHER CURRENT AND NON-CURRENT ASSETS.

All other current assets primarily include prepaid expenses and deferred costs, financing receivables, and derivative instruments. All other assets primarily include pension assets, equity method and other investments, financing receivables, long-term customer and sundry receivables, long-term inventories, and long-term contract and other deferred assets. All other current and non-current assets increased in the three months ended March 31, 2023, primarily due to assets transferred from GE as a result of the Spin-Off. Refer to Note 1, “Organization and Basis of Presentation” for further information.

ALL OTHER CURRENT AND NON-CURRENT LIABILITIES.

All other current liabilities and All other liabilities primarily include liabilities related to employee compensation and benefits, long-term contract liabilities, income taxes payable and uncertain tax positions, operating lease liabilities, sales allowances, equipment projects and other commercial liabilities, environmental, health and safety obligations, derivative instruments, product warranties, and accrued freight and utilities. All other current and non-current liabilities increased in the three months ended March 31, 2023, primarily due to liabilities transferred from GE as a result of the Spin-Off and the exercise of certain redeemable noncontrolling interests. Refer to Note 1, “Organization and Basis of Presentation” and “Redeemable noncontrolling interests” below for further information.

SUPPLY CHAIN FINANCE PROGRAMS.

The Company participates in voluntary supply chain finance programs which provide participating suppliers the opportunity to sell their GE HealthCare receivables to third parties at the sole discretion of both the suppliers and the third parties. We evaluate supply chain finance programs to ensure the use of a third-party intermediary to settle our trade payables does not change the nature, existence, amount, or timing of our trade payables and does not provide the Company with any direct economic benefit. If any characteristics of the trade payables change or we receive a direct economic benefit, we reclassify the trade payables as borrowings. In connection with the supply chain finance program, payment terms normally range from 30 to 150 days, not exceeding 180 days, depending on the underlying supplier agreements. Included in Accounts payable as of March 31, 2023 and December 31, 2022 were $390 million and $392 million, respectively, of confirmed supplier invoices that are outstanding and subject to the third-party programs.

REDEEMABLE NONCONTROLLING INTERESTS.

The Company has noncontrolling interests with redemption features. These redemption features, such as put options, could require the Company to purchase the noncontrolling interests upon the occurrence of certain events, such as a change of control of the Company. All noncontrolling interests with redemption features that are not solely within our control are recognized within the Condensed Consolidated and Combined Statements of Financial Position between liabilities and equity. Redeemable noncontrolling interests are initially recorded at the issuance date fair value. Those that are currently redeemable or probable of becoming redeemable are subsequently adjusted to the greater of current redemption value or initial carrying value. A change of control is generally not considered probable until it occurs.

The activity attributable to redeemable noncontrolling interests for the three months ended March 31, 2023 and 2022 is presented below.


Redeemable Noncontrolling Interests
	For the three months ended March 31
	2023		2022
Balance at beginning of period	$	230	$	220
Net income attributable to redeemable noncontrolling interests	10		9
Redemption value adjustments(a)	183		—
Exercise of redeemable noncontrolling interests(b)	(222)		—
Balance at end of period	$	201	$	229


Other Income (Expense) – Net
	For the three months ended March 31
	2023		2022
Net interest and investment income (expense)	$	13	$	(2)
Equity method investment income	4		3
Change in fair value of assumed obligation	(13)		—
Other items, net(a)	4		25
Total other income (expense) – net	$	8	$	26

(a) Other items, net primarily consists of licensing and royalty income and gains and losses related to derivatives for the three months ended March 31, 2022.

SUBSEQUENT EVENTS (Details)	Apr. 25, 2023 $ / shares
Subsequent event
Subsequent Event [Line Items]
Dividends declared (in dollars per share)	$ 0.03

COMMITMENTS, GUARANTEES, PRODUCT WARRANTIES, AND OTHER LOSS CONTINGENCIES (Tables)

3 Months Ended

Mar. 31, 2023

Commitments and Contingencies Disclosure [Abstract]

Schedule of Product Warranties

An analysis of changes in the liability for product warranties follows.


Product Warranties
	For the three months ended March 31
	2023		2022
Balance at beginning of period	$	193	$	161
Current-year provisions	49		55
Expenditures	(51)		(45)
Other changes	2		(1)
Balance at end of period	$	193	$	170

SUPPLEMENTAL FINANCIAL INFORMATION - Narrative (Details) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022
Supplier Finance Program [Line Items]
Supplier finance program, payment terms, maximum threshold	180 days
Supplier finance program obligation	$ 390	$ 392
Minimum
Supplier Finance Program [Line Items]
Supplier finance program, payment terms	30 days
Maximum
Supplier Finance Program [Line Items]
Supplier finance program, payment terms	150 days

ACQUISITIONS, GOODWILL, AND OTHER INTANGIBLE ASSETS - Schedule of Goodwill (Details) $ in Millions	3 Months Ended
	Mar. 31, 2023 USD ($)
Goodwill [Roll Forward]
Beginning balance	$ 12,813
Acquisitions	105
Foreign exchange and other	6
Ending balance	12,924
Imaging
Goodwill [Roll Forward]
Beginning balance	4,409
Acquisitions	0
Foreign exchange and other	4
Ending balance	4,413
Ultrasound
Goodwill [Roll Forward]
Beginning balance	3,835
Acquisitions	105
Foreign exchange and other	1
Ending balance	3,941
PCS
Goodwill [Roll Forward]
Beginning balance	2,036
Acquisitions	0
Foreign exchange and other	1
Ending balance	2,037
PDx
Goodwill [Roll Forward]
Beginning balance	2,533
Acquisitions	0
Foreign exchange and other	0
Ending balance	$ 2,533

- Definition

Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.

+ References + Details

PROPERTY, PLANT, AND EQUIPMENT AND OPERATING LEASES - Summary of Property, Plant and Equipment (Details) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Original cost	$ 5,060	$ 4,989
Less accumulated depreciation and amortization	(3,039)	(2,988)
Right-of-use operating lease assets	306	313
Property, plant, and equipment - net	$ 2,327	$ 2,314

REVENUE RECOGNITION - Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Contract liabilities	$ 2,681		$ 2,526
Contract liabilities, noncurrent	650		$ 630
Increase in contract liabilities, product growth, customer advances and deposits	155
Contract liabilities, revenue recognized	759	$ 715
Remaining performance obligation, amount	14,490
Products
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligation, amount	$ 4,966
Products \| Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-04-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligation, percentage	99.00%
Remaining performance obligation, period	2 years
Services
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligation, amount	$ 9,524
Services \| Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-04-01 \| Period one
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligation, percentage	67.00%
Remaining performance obligation, period	2 years
Services \| Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-04-01 \| Period two
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligation, percentage	97.00%
Remaining performance obligation, period	5 years

ORGANIZATION AND BASIS OF PRESENTATION (Policies)	3 Months Ended
ORGANIZATION AND BASIS OF PRESENTATION (Policies)	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION	BASIS OF PRESENTATION. The condensed consolidated and combined financial statements have been prepared in accordance with United States ("U.S.") generally accepted accounting principles (“U.S. GAAP”) and present the historical results of operations, comprehensive income, and cash flows for the three months ended March 31, 2023 and 2022 and the financial position as of March 31, 2023 and December 31, 2022. It is management’s opinion that these financial statements include all normal and recurring adjustments necessary for a fair presentation of the Company’s financial position and operating results. The following tables are presented in millions of U.S dollars ("USD") unless otherwise stated. Prior to the Spin-Off, the condensed combined financial statements were derived from the consolidated financial statements and accounting records of GE including the historical cost basis of assets and liabilities comprising the Company, as well as the historical revenues, direct costs, and allocations of indirect costs attributable to the operations of the Company, using the historical accounting policies applied by GE. The condensed combined financial statements do not purport to reflect what the results of operations, comprehensive income, financial position, or cash flows would have been had the Company operated as a separate, stand-alone entity during the periods presented. The condensed consolidated and combined financial statements should be read in conjunction with the Company’s audited combined financial statements and notes included in our Annual Report on Form 10-K for the year ended December 31, 2022.
CONSOLIDATION	All intercompany balances and transactions within the Company have been eliminated in the condensed consolidated and combined financial statements.
ESTIMATES AND ASSUMPTIONS	ESTIMATES AND ASSUMPTIONS. The preparation of the condensed consolidated and combined financial statements in conformity with U.S. GAAP requires management to make estimates based on assumptions about current, and for some estimates, future, economic and market conditions, which affect the reported amounts and related disclosures in the condensed consolidated and combined financial statements. We base our estimates and judgments on historical experience and on various other assumptions and information that we believe to be reasonable under the circumstances. Although our estimates contemplate current and expected future conditions, as applicable, it is reasonably possible that actual conditions could differ from our expectations, which could materially affect our results of operations, financial position, and cash flows. While there has not been a material impact to our accounting estimates as of March 31, 2023 and December 31, 2022 and the results for the three months ended March 31, 2023 and 2022, a number of estimates could be affected by the ongoing COVID-19 pandemic. The severity, magnitude, and duration, as well as the economic consequences of the COVID-19 pandemic, are uncertain and difficult to predict. As a result, our accounting estimates and assumptions may change over time in response to COVID-19. Such changes could result in future impairments of goodwill, intangible assets, long-lived assets, and investment securities, incremental credit losses on receivables, a decrease in the realizability of our tax assets, or an increase in our related obligations as of the time of a relevant measurement event.
ACCOUNTING CHANGES	ACCOUNTING CHANGES. Accounting Standards Codification (“ASC”) Topic 740, Income Taxes, provides that interest and penalties related to unrecognized income tax benefits may either be classified as income tax expense or interest expense in the condensed consolidated statements of operations. In the first quarter of 2023, the Company changed its accounting policy for presentation of interest expense on uncertain tax positions. The interest was previously presented within “Interest and other financial charges – net” and has changed to being presented within “Benefit (provision) for income taxes.” The Company believes this presentation is preferable because the cost is related to income tax matters and this presentation enhances comparability with our peers. The effects of the change in accounting have been prospectively applied to periods beginning in the first quarter of 2023 and were not material to any previously reported periods prior to March 31, 2023. Recent Accounting Pronouncements reflected in the Condensed Consolidated and Combined Financial Statements In September 2022, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2022-04, Liabilities – Supplier Finance Programs (Subtopic 405-50). The ASU requires companies to disclose information about supplier finance programs, including key terms of the program, outstanding confirmed amounts as of the end of the period, a rollforward of such amounts during each annual period, and a description of where the amounts are presented. The new standard does not affect the recognition, measurement, or financial statement presentation of supplier finance obligations. The ASU is effective for fiscal years beginning after December 15, 2022, including interim periods, except for rollforward information, which is effective for fiscal years beginning after December 15, 2023. The Company adopted this guidance on January 1, 2023. See Note 17, “Supplemental Financial Information” for further information. In October 2021, the FASB issued ASU No. 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. The ASU requires companies to apply the definition of a performance obligation under ASC 606, Revenue from Contracts with Customers, to recognize and measure contract assets and contract liabilities relating to contracts with customers acquired in a business combination. Prior to the adoption of this ASU, an acquirer generally recognized assets acquired and liabilities assumed in a business combination, including contract assets and contract liabilities arising from revenue contracts with customers, at fair value on the acquisition date. The ASU results in the acquirer recording acquired contract assets and liabilities on the same basis that would have been recorded by the acquiree before the acquisition under ASC 606. The ASU is effective for fiscal years beginning after December 15, 2022, with early adoption permitted. The Company adopted this guidance on January 1, 2023 using a prospective method, and the adoption did not have a material impact on the condensed consolidated financial statements.

PROPERTY, PLANT, AND EQUIPMENT AND OPERATING LEASES

3 Months Ended

Mar. 31, 2023

Property, Plant and Equipment [Abstract]

PROPERTY, PLANT, AND EQUIPMENT AND OPERATING LEASES


Property, Plant, and Equipment - Net
	As of
	March 31, 2023		December 31, 2022
Original cost	$	5,060	$	4,989
Less accumulated depreciation and amortization	(3,039)		(2,988)
Right-of-use operating lease assets	306		313
Property, plant, and equipment - net	$	2,327	$	2,314

OPERATING LEASE LIABILITIES.

Operating lease liabilities recognized within all other current and non-current liabilities in the Condensed Consolidated and Combined Statements of Financial Position were $341 million and $347 million as of March 31, 2023 and December 31, 2022, respectively. Expense related to our operating lease portfolio was $56 million for both the three months ended March 31, 2023 and 2022.

REVENUE RECOGNITION - Summary of Contract and Other Deferred Assets (Details) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022
Revenue from Contract with Customer [Abstract]
Contract assets	$ 593	$ 584
Other deferred assets	390	405
Contract and other deferred assets	983	989
Non-current contract assets	38	37
Non-current other deferred assets	81	82
Total contract and other deferred assets	$ 1,102	$ 1,108

BORROWINGS

3 Months Ended

Mar. 31, 2023

Debt Disclosure [Abstract]

BORROWINGS

The Company’s borrowings include the following senior unsecured notes and credit agreements:

Senior Unsecured Notes

The Company’s long-term borrowings include $8,250 million aggregate principal amount of senior unsecured notes in six series with maturity dates ranging from 2024 through 2052 (collectively, the “Notes”).

Credit Facilities

The Company has credit agreements providing for:

•a five-year senior unsecured revolving credit facility in an aggregate committed amount of $2,500 million;

•a 364-day senior unsecured revolving credit facility in an aggregate committed amount of $1,000 million; and

•a three-year senior unsecured term loan credit facility in an aggregate principal amount of $2,000 million (the “Term Loan Facility” and, together with the five-year revolving credit facility and the 364-day revolving credit facility, the “Credit Facilities”).

There were no outstanding amounts under the five-year revolving credit facility and 364-day revolving credit facility as of March 31, 2023 or December 31, 2022. On January 3, 2023, the Company completed a $2,000 million drawdown of the Term Loan Facility in connection with the Spin-Off from GE.

The average interest rate for the Notes and our Credit Facilities for the three months ended March 31, 2023 was 5.94%. We had no principal debt repayments on the Notes or the Credit Facilities for the three months ended March 31, 2023.


Long-Term Borrowings Composition
	As of
	March 31, 2023		December 31, 2022
5.550% senior notes due November 15, 2024	$	1,000	$	1,000
5.600% senior notes due November 15, 2025	1,500		1,500
5.650% senior notes due November 15, 2027	1,750		1,750
5.857% senior notes due March 15, 2030	1,250		1,250
5.905% senior notes due November 22, 2032	1,750		1,750
6.377% senior notes due November 22, 2052	1,000		1,000
Term Loan Facility	2,000		—
Other	33		38
Total principal debt issued	10,283		8,288
Less: Unamortized debt issuance costs and discounts	44		47
Less: Current portion of long-term borrowings	5		7
Long-term borrowings, net of current portion	$	10,234	$	8,234

See Note 12, “Financial Instruments and Fair Value Measurements” for further information about borrowings and associated interest rate and cross-currency swaps.

LETTERS OF CREDIT, GUARANTEES, AND OTHER COMMITMENTS.

In addition to the Notes, which were guaranteed on a senior unsecured basis by GE through the completion of the Spin-Off, at which time GE was automatically and unconditionally released and discharged from all obligations under its guarantees, as of March 31, 2023 and December 31, 2022, the Company had unused letters of credit, bank guarantees, bid bonds, and surety bonds of approximately $675 million and $657 million, respectively, related to certain commercial contracts. Additionally, we have approximately $44 million and $43 million of guarantees as of March 31, 2023 and December 31, 2022, respectively, primarily related to residual value guarantees on equipment sold to third-party finance companies. Our Condensed Consolidated and Combined Statements of Financial Position reflects a liability of $4 million and $4 million as of March 31, 2023 and December 31, 2022, respectively, related to these guarantees. For credit-related guarantees, we estimate our expected credit losses related to off-balance sheet credit exposure consistent with the method used to estimate the allowance for credit losses on financial assets held at amortized cost. See Note 13, “Commitments, Guarantees, Product Warranties, and Other Loss Contingencies” for further information on guarantee arrangements with GE.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI https://asc.fasb.org/topic&trid=2208564

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1E
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

+ Details

FINANCING RECEIVABLES - Narrative (Details)	Mar. 31, 2023	Dec. 31, 2022
Financing Receivable, Past Due [Line Items]
Financing receivable, nonaccrual, percent past due	5.00%	6.00%
Over 30 days past due
Financing Receivable, Past Due [Line Items]
Financing receivable, percent past due	6.00%	7.00%
Over 90 days past due
Financing Receivable, Past Due [Line Items]
Financing receivable, percent past due	4.00%	6.00%

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Tables)

3 Months Ended

Mar. 31, 2023

Fair Value Disclosures [Abstract]

Schedule of Derivative Assets at Fair Value

The following table presents the gross fair values of our outstanding derivative instruments as of the dates indicated:


Fair Value of Derivatives
	March 31, 2023						December 31, 2022
	Gross Notional		Fair Value – Assets		Fair Value – Liabilities		Gross Notional		Fair Value – Assets		Fair Value – Liabilities
Foreign currency exchange contracts	$	1,226	$	25	$	62	$	1,240	$	32	$	53
Derivatives accounted for as cash flow hedges	1,226		25		62		1,240		32		53
Cross-currency swaps	2,176		21		167		2,132		—		111
Derivatives accounted for as net investment hedges	2,176		21		167		2,132		—		111
Foreign currency exchange contracts	4,690		38		22		4,456		9		20
Embedded derivatives	594		19		14		604		24		18
Equity contracts	231		15		3		8		—		6
Commodity derivatives	54		1		3		48		1		1
Derivatives not designated as hedges	5,569		73		42		5,116		34		45
Total derivatives	$	8,971	$	119	$	271	$	8,488	$	66	$	209

Schedule of Derivative Liabilities at Fair Value

The following table presents the gross fair values of our outstanding derivative instruments as of the dates indicated:


Fair Value of Derivatives
	March 31, 2023						December 31, 2022
	Gross Notional		Fair Value – Assets		Fair Value – Liabilities		Gross Notional		Fair Value – Assets		Fair Value – Liabilities
Foreign currency exchange contracts	$	1,226	$	25	$	62	$	1,240	$	32	$	53
Derivatives accounted for as cash flow hedges	1,226		25		62		1,240		32		53
Cross-currency swaps	2,176		21		167		2,132		—		111
Derivatives accounted for as net investment hedges	2,176		21		167		2,132		—		111
Foreign currency exchange contracts	4,690		38		22		4,456		9		20
Embedded derivatives	594		19		14		604		24		18
Equity contracts	231		15		3		8		—		6
Commodity derivatives	54		1		3		48		1		1
Derivatives not designated as hedges	5,569		73		42		5,116		34		45
Total derivatives	$	8,971	$	119	$	271	$	8,488	$	66	$	209

Schedule of Derivative Pre-tax Gains (Losses) Recognized in OCI

The table below presents the pre-tax gains (losses) recognized in OCI associated with the Company’s cash flow and net investment hedges:


Pre-tax Gains (Losses) Recognized in OCI Related to Cash flow and Net Investment Hedges
	For the three months ended March 31
	2023		2022
Cash flow hedges	$	(17)	$	41
Net investment hedges	35		—

Effect of Derivatives Instruments on Statements of Income

The table below presents the gains (losses) of our derivative financial instruments in the Condensed Consolidated and Combined Statements of Income:


Derivative Financial Instruments
	For the three months ended March 31, 2023								For the three months ended March 31, 2022
	Cost of products		Cost of services		Selling, general and administrative		Other (a)		Cost of products		Cost of services		Selling, general and administrative		Other (a)

Foreign currency exchange contracts	$	27	$	6	$	—	$	—	$	9	$	2	$	—	$	—
Effects of cash flow hedges	27		6		—		—		9		2		—		—
Cross-currency swaps	—		—		—		—		—		—		—		—
Effects of net investment hedges	—		—		—		—		—		—		—		—
Foreign currency exchange contracts	7		2		—		1		(1)		—		—		—
Embedded derivatives	—		—		—		(1)		—		—		—		3
Equity contracts	—		—		15		3		—		—		—		—
Commodity derivatives	—		—		—		(2)		—		—		—		10
Effect of derivatives not designated as hedges	$	7	$	2	$	15	$	1	$	(1)	$	—	$	—	$	13

(a) Amounts inclusive of Other income (expense) - net on the Condensed Consolidated and Combined Statements of Income.

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis

The following table represents financial assets and liabilities that are recorded and measured at fair value on a recurring basis:


Fair Value of Financial Assets and Liabilities
	March 31, 2023								December 31, 2022
	Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
Assets:
Investment securities	$	31	$	—	$	—	$	31	$	21	$	—	$	—	$	21
Derivatives	—		119		—		119		—		66		—		66
Liabilities:
Deferred compensation(a)	264		3		—		267		62		2		—		64
Derivatives	—		268		3		271		—		203		6		209
Contingent consideration	—		—		57		57		—		—		42		42

(a) Certain deferred compensation plans whose value is derived from market-based securities values were transferred from GE as part of the Spin-Off.

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022
Assets:
Investment securities	$ 31	$ 21
Derivatives	119	66
Liabilities:
Deferred compensation	267	64
Derivatives	271	209
Contingent consideration	57	42
Level 1
Assets:
Investment securities	31	21
Derivatives	0	0
Liabilities:
Deferred compensation	264	62
Derivatives	0	0
Contingent consideration	0	0
Level 2
Assets:
Investment securities	0	0
Derivatives	119	66
Liabilities:
Deferred compensation	3	2
Derivatives	268	203
Contingent consideration	0	0
Level 3
Assets:
Investment securities	0	0
Derivatives	0	0
Liabilities:
Deferred compensation	0	0
Derivatives	3	6
Contingent consideration	$ 57	$ 42

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Derivative [Line Items]
AOCI, cash flow hedge cumulative net gain	$ (30)
Cash flow hedge gain to be reclassified within 12 months	(27)
Cash flow hedges, pre-tax gains (losses) reclassified from AOCI into earnings	$ 33	$ 11
Maximum length of time hedged in cash flow hedge	2 years
Notional amount	$ 8,971		$ 8,488
Derivative, potential effect of rights of offset to assets and liabilities	56
Equity investments without readily determinable fair value	119		117
Estimated fair value
Derivative [Line Items]
Long-term debt	10,819		8,512
Carrying value
Derivative [Line Items]
Long-term debt	10,239		8,241
Net investment hedges \| Designated as hedging instrument
Derivative [Line Items]
Notional amount	2,176		2,132
Cross-currency swaps \| Net investment hedges \| Designated as hedging instrument
Derivative [Line Items]
Notional amount	$ 2,176		$ 2,132

ORGANIZATION AND BASIS OF PRESENTATION (Details) - USD ($) $ / shares in Units, $ in Millions			3 Months Ended
	Jan. 03, 2023	Dec. 31, 2022	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Sale of stock, percent of stock distributed	80.10%
Sale of stock, number of shares issued	454,000,000	100
Sale of stock, price per share (in dollars per share)		$ 1.00
Net transfers from Parent, including Spin-Off-related adjustments, equity reduction			$ 2,834
Separation-related adjustments, deferred compensation liability			$ 548

EARNINGS PER SHARE - Narrative (Details) - shares	Jan. 03, 2023	Mar. 31, 2023	Dec. 31, 2022
Earnings Per Share [Abstract]
Common stock, outstanding (in shares)	454,000,000	454,617,131	100
Sale of stock, ownership after transaction	19.90%

Condensed Consolidated and Combined Statements of Income (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenue	$ 4,707	$ 4,343
Gross profit	1,891	1,678
Selling, general, and administrative	1,062	931
Research and development	270	238
Total operating expenses	1,332	1,169
Operating income (loss)	559	509
Interest and other financial charges – net	136	4
Non-operating benefit (income) costs	(115)	(2)
Other (income) expense – net	(8)	(26)
Income from continuing operations before income taxes	546	533
Benefit (provision) for income taxes	(163)	(131)
Net income	383	402
Net (income) attributable to noncontrolling interests	(11)	(13)
Net income attributable to GE HealthCare	372	389
Deemed preferred stock dividend of redeemable noncontrolling interest	(183)	0
Net income attributable to GE HealthCare common stockholders	$ 189	$ 389
Earnings per share:
Basic earnings per share (in dollars per share)	$ 0.42	$ 0.86
Diluted earnings per share (in dollars per share)	$ 0.41	$ 0.86
Weighted-average number of shares outstanding:
Basic (in shares)	454	454
Diluted (in shares)	457	454
Products
Revenue	$ 3,131	$ 2,787
Cost of revenue	2,037	1,914
Services
Revenue	1,576	1,556
Cost of revenue	$ 779	$ 751

ACQUISITIONS, GOODWILL, AND OTHER INTANGIBLE ASSETS (Tables)

3 Months Ended

Mar. 31, 2023

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Goodwill


Goodwill
	Balance as of December 31, 2022		Acquisitions		Foreign exchange and other		Balance as of March 31, 2023
Imaging	$	4,409	$	—	$	4	$	4,413
Ultrasound	3,835		105		1		3,941
PCS	2,036		—		1		2,037
PDx	2,533		—		—		2,533
Total Goodwill	$	12,813	$	105	$	6	$	12,924

- Definition

Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1A
-URI https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 55
-Paragraph 24
-URI https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

+ Details

POSTRETIREMENT BENEFIT PLANS - Schedule of Defined Benefit Plans (Details) $ in Millions	Jan. 01, 2023 USD ($)
Accumulated Benefit Obligations and Unrecognized Gain
Accumulated benefit obligations	$ 22,906
Unrecognized gain to be recorded in AOCI	2,481
Net Benefit Liability
Projected benefit obligations	22,953
Fair value of assets	18,908
Net liability	4,045
Defined benefit plans
Accumulated Benefit Obligations and Unrecognized Gain
Accumulated benefit obligations	21,696
Unrecognized gain to be recorded in AOCI	1,258
Net Benefit Liability
Projected benefit obligations	21,743
Fair value of assets	18,908
Net liability	2,835
Other postretirement plans
Accumulated Benefit Obligations and Unrecognized Gain
Accumulated benefit obligations	1,210
Unrecognized gain to be recorded in AOCI	1,223
Net Benefit Liability
Projected benefit obligations	1,210
Fair value of assets	0
Net liability	$ 1,210

- Definition

Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.

+ References + Details

SHARE-BASED COMPENSATION

3 Months Ended

Mar. 31, 2023

Share-Based Payment Arrangement [Abstract]

SHARE-BASED COMPENSATION

We grant stock options, restricted stock units (“RSU”), and performance share units (“PSU”) to employees under the 2023 Long-Term Incentive Plan (“LTIP”). The Talent, Culture, and Compensation Committee of the Board of Directors approves grants under the LTIP. Under the LTIP, we are authorized to issue up to approximately 41 million shares. We record compensation expense for awards expected to vest over the vesting period. We estimate forfeitures based on experience and adjust expense to reflect actual forfeitures. When options are exercised, RSUs vest, and PSUs are earned, we issue shares from authorized unissued common stock.

Stock options provide employees the opportunity to purchase GE HealthCare shares in the future at the market price of our stock on the date the award is granted (the strike price). The options become exercisable over the vesting period, typically becoming fully vested in three to three and a half years, and expire ten years from the grant date if not exercised. An RSU provides an employee the right to one share of GE HealthCare stock when the restrictions lapse over the vesting period. Upon vesting, each RSU is converted into one share of GE HealthCare common stock. PSUs provide an employee with the right to receive shares of GE HealthCare stock based upon achievement of certain performance and market metrics. Upon vesting, each PSU earned is converted into shares of GE HealthCare common stock. We value stock options using a Black-Scholes option pricing model, RSUs using the market price on the grant date, and PSUs using the market price on the grant date and a Monte Carlo simulation as needed based on performance metrics.

The following tables provide the weighted average fair value of options, RSUs, and PSUs granted to employees during the three months ended March 31, 2023 and the related stock option valuation assumptions used in the Black-Scholes model:


Weighted Average Grant Date Fair Value
(In dollars)	March 31, 2023
Stock options	$	25
RSUs	72
PSUs	84


Key Assumptions in the Black-Scholes Valuation for Stock Options
	March 31, 2023
Risk free rate	3.6		%
Dividend yield	—		%
Expected volatility	26.5		%
Expected term (in years)	6.3
Strike price (in dollars)	$	71

For new awards granted in 2023, the expected volatility was derived from a peer group’s blended historical and implied volatility as GE HealthCare does not have sufficient historical volatility based on the expected term of the underlying options. The expected term of the stock options was determined using the simplified method. The risk-free interest rate was determined using the implied yield currently available for zero-coupon U.S. government issues with a remaining term approximating the expected life of the options. The dividend yield input was zero as it was uncertain if a dividend would be paid at the time of the grant.


Share-Based Compensation Activity
	Stock options						RSUs
	Shares (in thousands)	Weighted average exercise price (in dollars)		Weighted average contractual term (in years)	Intrinsic value (in millions)		Shares (in thousands)	Weighted average grant date fair value (in dollars)		Weighted average contractual term (in years)	Intrinsic value (in millions)
Outstanding as of January 4, 2023(a)	3,738	$	90				3,551	$	58
Granted	2,037	71					1,612	72
Exercised/Vested	(326)	56					(558)	70
Forfeited	(3)	68					(52)	63
Expired	(5)	143					—	—
Outstanding as of March 31, 2023	5,441	$	85	6.6	$	57	4,553	$	63	2.0	$	374
Exercisable as of March 31, 2023	3,182	$	94	4.3	$	33	N/A	N/A		N/A	N/A
Expected to vest	1,681	$	71	9.7	$	18	3,817	$	54	2.0	$	313

(a) Our common stock began “regular way” trading on The Nasdaq Global Market on January 4, 2023. The shares outstanding as of January 4, 2023 pertain to GE equity-based awards issued by GE in prior periods to employees of the Company that were converted to GE HealthCare equity-based awards as part of the Spin-Off.

Total outstanding PSUs as of March 31, 2023 were 1,271 thousand shares with a weighted average fair value of $85 dollars. The intrinsic value and weighted average contractual term of PSUs outstanding were $104 million and 2.0 years, respectively.

The following tables present compensation expense and tax impact recognized as well as other share-based compensation data for the three months ended March 31, 2023.


Share-based Compensation Expense
	March 31, 2023



Compensation expense (pre-tax)	$	24
Income tax benefits	(8)
Compensation expense (after-tax)	$	16


Other Share-based Compensation Data
	March 31, 2023
Unrecognized compensation expense (amortized over a weighted average period of 2.0 years)	$	212
Cash received from stock options exercised	18
Intrinsic value of stock options exercised and RSU/PSUs vested	48

POSTRETIREMENT BENEFIT PLANS - Narrative (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan liability			$ 0
Plan asset or obligation reporting threshold	$ 50,000,000	$ 20,000,000
Defined benefit plan, expected future employer contributions, remainder of fiscal year	255,000,000
Defined benefit plan, expected future employer contributions, plans no longer disclosed	11,000,000
Defined contribution plan, employer contribution amount	33,000,000	31,000,000
Pension plans
Defined Benefit Plan Disclosure [Line Items]
Net periodic postretirement benefit plan (income) expense	(80,000,000)	3,000,000
Defined benefit plan, employer contribution amount	48,000,000
Other postretirement plans
Defined Benefit Plan Disclosure [Line Items]
Net periodic postretirement benefit plan (income) expense	(21,000,000)	0
Defined benefit plan, employer contribution amount	$ 43,000,000
U.S. GE Principal Pension and Principal Retiree Benefit Plans
Defined Benefit Plan Disclosure [Line Items]
Net periodic postretirement benefit plan (income) expense		24,000,000
Non-U.S. GE Pension Plan
Defined Benefit Plan Disclosure [Line Items]
Net periodic postretirement benefit plan (income) expense		$ 4,000,000

EARNINGS PER SHARE

3 Months Ended

Mar. 31, 2023

Earnings Per Share [Abstract]

EARNINGS PER SHARE

EARNINGS PER SHAREOn January 3, 2023, there were approximately 454 million shares of GE HealthCare common stock outstanding, including the 19.9% interest in our outstanding shares of common stock retained by GE following the Distribution. The computation of basic and diluted earnings per common share for all periods through December 31, 2022 was calculated using this same number of common shares outstanding since no GE HealthCare equity awards were outstanding as of the Distribution Date and is net of Net (income) loss attributable to noncontrolling interest which is fully associated with continuing operations.


Earnings Per Share
	For the three months ended March 31
(In millions, except per share amounts)	2023		2022
Numerator:
Net income	$	383	$	402
Net (income) attributable to noncontrolling interests	(11)		(13)
Net income attributable to GE HealthCare	372		389
Deemed preferred stock dividend of redeemable noncontrolling interest	(183)		—

Net income attributable to GE HealthCare common stockholders	$	189	$	389
Denominator:
Basic weighted-average shares outstanding	454		454
Dilutive effect of common stock equivalents	3		—
Diluted weighted-average shares outstanding	457		454
Basic Earnings Per Share	$	0.42	$	0.86



Diluted Earnings Per Share	$	0.41	$	0.86



Antidilutive securities(a)	4		—

(a) Diluted EPS excludes certain shares issuable under stock based compensation plans because the effect would have been antidilutive.

SEGMENT INFORMATION - Narrative (Details)	3 Months Ended
SEGMENT INFORMATION - Narrative (Details)	Mar. 31, 2023 segment
Segment Reporting [Abstract]
Number of operating segments	4
Number of reportable segments	4

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Schedule of Derivative Fair Values (Details) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022
Derivative [Line Items]
Gross Notional	$ 8,971	$ 8,488
Fair Value – Assets	119	66
Fair Value – Liabilities	271	209
Designated as hedging instrument \| Cash flow hedges
Derivative [Line Items]
Gross Notional	1,226	1,240
Fair Value – Assets	25	32
Fair Value – Liabilities	62	53
Designated as hedging instrument \| Cash flow hedges \| Foreign currency exchange contracts
Derivative [Line Items]
Gross Notional	1,226	1,240
Fair Value – Assets	25	32
Fair Value – Liabilities	62	53
Designated as hedging instrument \| Net investment hedges
Derivative [Line Items]
Gross Notional	2,176	2,132
Fair Value – Assets	21	0
Fair Value – Liabilities	167	111
Designated as hedging instrument \| Net investment hedges \| Cross-currency swaps
Derivative [Line Items]
Gross Notional	2,176	2,132
Fair Value – Assets	21	0
Fair Value – Liabilities	167	111
Not designated as hedging instrument
Derivative [Line Items]
Gross Notional	5,569	5,116
Fair Value – Assets	73	34
Fair Value – Liabilities	42	45
Not designated as hedging instrument \| Foreign currency exchange contracts
Derivative [Line Items]
Gross Notional	4,690	4,456
Fair Value – Assets	38	9
Fair Value – Liabilities	22	20
Not designated as hedging instrument \| Embedded derivatives
Derivative [Line Items]
Gross Notional	594	604
Fair Value – Assets	19	24
Fair Value – Liabilities	14	18
Not designated as hedging instrument \| Equity contracts
Derivative [Line Items]
Gross Notional	231	8
Fair Value – Assets	15	0
Fair Value – Liabilities	3	6
Not designated as hedging instrument \| Commodity derivatives
Derivative [Line Items]
Gross Notional	54	48
Fair Value – Assets	1	1
Fair Value – Liabilities	$ 3	$ 1

SUPPLEMENTAL FINANCIAL INFORMATION - Schedule of Other Income (Expense) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net interest and investment income (expense)	$ 13	$ (2)
Equity method investment income	4	3
Change in fair value of assumed obligation	(13)	0
Other items, net	4	25
Total other income (expense) – net	$ 8	$ 26

INCOME TAXES	3 Months Ended
INCOME TAXES	Mar. 31, 2023
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES Our income tax rate was 29.9% and 24.6% for the three months ended March 31, 2023 and 2022, respectively. The tax rate for 2023 is higher than the U.S. statutory rate primarily due to the cost of global activities, including the U.S. taxation on international operations, withholding taxes, and state taxes. The tax rate for 2022 is higher than the U.S. statutory rate primarily due to the cost of global activities, including the U.S. taxation on international operations and state taxes. The Company is currently being audited in a number of jurisdictions for tax years 2004-2021, including China, Egypt, France, Germany, Norway, the United Kingdom, and the U.S. In the first quarter of 2023, the Company changed its accounting policy for presentation of interest expense on uncertain tax positions from within “Interest and other financial charges – net” to within “Benefit (provision) for income taxes.” See Note 1, “Organization and Basis of Presentation” for further information. Post Spin-Off, the Company’s previously undistributed earnings of certain of our foreign subsidiaries are no longer indefinitely reinvested in non-U.S. businesses due to current U.S. funding needs. Therefore, an incremental deferred tax liability of $30 million has been recorded for withholding and other foreign taxes due upon future distribution of earnings. In addition, the Company is providing for withholding and other foreign taxes due upon future distribution of current period earnings. Also, in connection with the Spin-Off, our net deferred income tax assets increased by $3,099 million primarily due to transfers from GE, including $964 million related to pension and postretirement benefits, with the remainder primarily attributable to tax attributes that were not part of the Company’s stand-alone operations, and changes to valuation on a GE HealthCare basis.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI https://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) – NET (Tables)

3 Months Ended

Mar. 31, 2023

Equity [Abstract]

Schedule of Accumulated Other Comprehensive Income (Loss)

Changes in Accumulated other comprehensive income (loss) (“AOCI”) by component, net of income taxes, for the three months ended March 31, 2023 and 2022 were as follows:


	For the three months ended March 31, 2023
	Currency translation adjustments(a)		Benefit plans		Cash flow hedges		Total AOCI
December 31, 2022	$	(1,845)	$	(42)	$	9	$	(1,878)
Other comprehensive income (loss) before reclasses – net of taxes of $(11), $2, and $4	85		(13)		(13)		59
Unrecognized gain transferred from GE pension – net of taxes of $0, $(509), and $0(b)	—		1,972		—		1,972
Reclasses from AOCI – net of taxes of $0, $16, and $7	—		(52)		(26)		(78)


March 31, 2023	$	(1,760)	$	1,865	$	(30)	$	75


	For the three months ended March 31, 2022
	Currency translation adjustments(a)		Benefit plans		Cash flow hedges		Total AOCI
December 31, 2021	$	(969)	$	(100)	$	32	$	(1,037)
Other comprehensive income (loss) before reclasses – net of taxes of $(2), $(9), and $(6)	(153)		(5)		35		(123)

Reclasses from AOCI – net of taxes of $0, $0, and $0	—		—		(11)		(11)


March 31, 2022	$	(1,122)	$	(105)	$	56	$	(1,171)

(a) The amount of foreign currency translation recognized in Other comprehensive income (loss) during the three months ended March 31, 2023 and 2022 included net gains (losses) relating to net investment hedges, as further discussed in Note 12, “Financial Instruments and Fair Value Measurements.”

(b) Refer to Note 9, “Postretirement Benefit Plans” for further information on the unrecognized gain transferred from GE pension in connection with the Spin-Off.

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Effect of Derivatives Instruments on Statements of Income (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Derivative Instruments, Gain (Loss) [Line Items]
Effects of cash flow hedges	$ 33	$ 11
Selling, general and administrative
Derivative Instruments, Gain (Loss) [Line Items]
Effects of cash flow hedges	0	0
Effects of net investment hedges	0	0
Effect of derivatives not designated as hedges	15	0
Selling, general and administrative \| Foreign currency exchange contracts
Derivative Instruments, Gain (Loss) [Line Items]
Effects of cash flow hedges	0	0
Effect of derivatives not designated as hedges	0	0
Selling, general and administrative \| Cross-currency swaps
Derivative Instruments, Gain (Loss) [Line Items]
Effects of net investment hedges	0	0
Selling, general and administrative \| Embedded derivatives
Derivative Instruments, Gain (Loss) [Line Items]
Effect of derivatives not designated as hedges	0	0
Selling, general and administrative \| Equity contracts
Derivative Instruments, Gain (Loss) [Line Items]
Effect of derivatives not designated as hedges	15	0
Selling, general and administrative \| Commodity derivatives
Derivative Instruments, Gain (Loss) [Line Items]
Effect of derivatives not designated as hedges	0	0
Other
Derivative Instruments, Gain (Loss) [Line Items]
Effects of cash flow hedges	0	0
Effects of net investment hedges	0	0
Effect of derivatives not designated as hedges	1	13
Other \| Foreign currency exchange contracts
Derivative Instruments, Gain (Loss) [Line Items]
Effects of cash flow hedges	0	0
Effect of derivatives not designated as hedges	1	0
Other \| Cross-currency swaps
Derivative Instruments, Gain (Loss) [Line Items]
Effects of net investment hedges	0	0
Other \| Embedded derivatives
Derivative Instruments, Gain (Loss) [Line Items]
Effect of derivatives not designated as hedges	(1)	3
Other \| Equity contracts
Derivative Instruments, Gain (Loss) [Line Items]
Effect of derivatives not designated as hedges	3	0
Other \| Commodity derivatives
Derivative Instruments, Gain (Loss) [Line Items]
Effect of derivatives not designated as hedges	(2)	10
Products \| Cost of revenue
Derivative Instruments, Gain (Loss) [Line Items]
Effects of cash flow hedges	27	9
Effects of net investment hedges	0	0
Effect of derivatives not designated as hedges	7	(1)
Products \| Cost of revenue \| Foreign currency exchange contracts
Derivative Instruments, Gain (Loss) [Line Items]
Effects of cash flow hedges	27	9
Effect of derivatives not designated as hedges	7	(1)
Products \| Cost of revenue \| Cross-currency swaps
Derivative Instruments, Gain (Loss) [Line Items]
Effects of net investment hedges	0	0
Products \| Cost of revenue \| Embedded derivatives
Derivative Instruments, Gain (Loss) [Line Items]
Effect of derivatives not designated as hedges	0	0
Products \| Cost of revenue \| Equity contracts
Derivative Instruments, Gain (Loss) [Line Items]
Effect of derivatives not designated as hedges	0	0
Products \| Cost of revenue \| Commodity derivatives
Derivative Instruments, Gain (Loss) [Line Items]
Effect of derivatives not designated as hedges	0	0
Services \| Cost of revenue
Derivative Instruments, Gain (Loss) [Line Items]
Effects of cash flow hedges	6	2
Effects of net investment hedges	0	0
Effect of derivatives not designated as hedges	2	0
Services \| Cost of revenue \| Foreign currency exchange contracts
Derivative Instruments, Gain (Loss) [Line Items]
Effects of cash flow hedges	6	2
Effect of derivatives not designated as hedges	2	0
Services \| Cost of revenue \| Cross-currency swaps
Derivative Instruments, Gain (Loss) [Line Items]
Effects of net investment hedges	0	0
Services \| Cost of revenue \| Embedded derivatives
Derivative Instruments, Gain (Loss) [Line Items]
Effect of derivatives not designated as hedges	0	0
Services \| Cost of revenue \| Equity contracts
Derivative Instruments, Gain (Loss) [Line Items]
Effect of derivatives not designated as hedges	0	0
Services \| Cost of revenue \| Commodity derivatives
Derivative Instruments, Gain (Loss) [Line Items]
Effect of derivatives not designated as hedges	$ 0	$ 0

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) – NET

3 Months Ended

Mar. 31, 2023

Equity [Abstract]

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) – NET

Changes in Accumulated other comprehensive income (loss) (“AOCI”) by component, net of income taxes, for the three months ended March 31, 2023 and 2022 were as follows:


	For the three months ended March 31, 2023
	Currency translation adjustments(a)		Benefit plans		Cash flow hedges		Total AOCI
December 31, 2022	$	(1,845)	$	(42)	$	9	$	(1,878)
Other comprehensive income (loss) before reclasses – net of taxes of $(11), $2, and $4	85		(13)		(13)		59
Unrecognized gain transferred from GE pension – net of taxes of $0, $(509), and $0(b)	—		1,972		—		1,972
Reclasses from AOCI – net of taxes of $0, $16, and $7	—		(52)		(26)		(78)


March 31, 2023	$	(1,760)	$	1,865	$	(30)	$	75


	For the three months ended March 31, 2022
	Currency translation adjustments(a)		Benefit plans		Cash flow hedges		Total AOCI
December 31, 2021	$	(969)	$	(100)	$	32	$	(1,037)
Other comprehensive income (loss) before reclasses – net of taxes of $(2), $(9), and $(6)	(153)		(5)		35		(123)

Reclasses from AOCI – net of taxes of $0, $0, and $0	—		—		(11)		(11)


March 31, 2022	$	(1,122)	$	(105)	$	56	$	(1,171)

(b) Refer to Note 9, “Postretirement Benefit Plans” for further information on the unrecognized gain transferred from GE pension in connection with the Spin-Off.

PROPERTY, PLANT, AND EQUIPMENT AND OPERATING LEASES (Tables)

3 Months Ended

Mar. 31, 2023

Property, Plant and Equipment [Abstract]

Summary of Property, Plant and Equipment


Property, Plant, and Equipment - Net
	As of
	March 31, 2023		December 31, 2022
Original cost	$	5,060	$	4,989
Less accumulated depreciation and amortization	(3,039)		(2,988)
Right-of-use operating lease assets	306		313
Property, plant, and equipment - net	$	2,327	$	2,314

RELATED PARTIES - Narrative (Details) $ in Millions	3 Months Ended
RELATED PARTIES - Narrative (Details) $ in Millions	Mar. 31, 2023 USD ($) director	Mar. 31, 2022 USD ($)
GE, before spin-off \| Separation costs related to pension, benefit and contribution plans
Related Party Transaction [Line Items]
Transaction amount		$ 59
GE, before spin-off \| Share-based compensation expense
Related Party Transaction [Line Items]
Transaction amount		$ 19
GE, after spin-off
Related Party Transaction [Line Items]
Due from related parties, non-current	$ 77
Due to related parties, non-current	108
GE, after spin-off \| Transition Services Agreement
Related Party Transaction [Line Items]
Transaction amount	$ 108
Agreement term	36 months
GE, after spin-off \| Tax Matters Agreement
Related Party Transaction [Line Items]
Period following distribution date	2 years
Directors \| Product and service sales
Related Party Transaction [Line Items]
Number of board members \| director	2
Revenue from related parties	$ 24

Condensed Consolidated and Combined Statements of Financial Position (Unaudited) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Cash, cash equivalents, and restricted cash	$ 2,327	$ 1,445
Receivables – net of allowances of $91 and $91	3,373	3,295
Due from related parties	31	17
Inventories	2,256	2,155
Contract and other deferred assets	983	989
All other current assets	634	417
Current assets	9,604	8,318
Property, plant, and equipment – net	2,327	2,314
Goodwill	12,924	12,813
Other intangible assets – net	1,494	1,520
Deferred income taxes	4,336	1,550
All other assets	1,952	1,024
Total assets	32,637	27,539
Short-term borrowings	5	15
Accounts payable	2,977	2,944
Due to related parties	186	146
Contract liabilities	2,031	1,896
All other current liabilities	3,037	2,190
Current liabilities	8,236	7,191
Long-term borrowings	10,234	8,234
Compensation and benefits	5,372	549
Deferred income taxes	64	370
All other liabilities	1,834	1,603
Total liabilities	25,740	17,947
Commitments and contingencies
Redeemable noncontrolling interests	201	230
Common stock, par value $0.01 per share, 1,000,000,000 shares authorized, 454,617,131 shares issued and outstanding as of March 31, 2023; 100 shares issued and outstanding as of December 31, 2022	5	0
Additional paid-in capital	6,425	0
Retained earnings	185	0
Net parent investment	0	11,235
Accumulated other comprehensive income (loss) – net	75	(1,878)
Total equity attributable to GE HealthCare	6,690	9,357
Noncontrolling interests	6	5
Total equity	6,696	9,362
Total liabilities, redeemable noncontrolling interests, and equity	$ 32,637	$ 27,539

ACQUISITIONS, GOODWILL, AND OTHER INTANGIBLE ASSETS - Narrative (Details) - USD ($) $ in Millions		3 Months Ended
	Feb. 17, 2023	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Business Acquisition [Line Items]
Consideration transferred, upfront payment		$ 127	$ 0
Contingent consideration		57		$ 42
Goodwill		12,924		$ 12,813
Amortization of acquisition-related intangible assets		96	$ 103
Caption Health
Business Acquisition [Line Items]
Percent of interest acquired	100.00%
Consideration transferred, upfront payment	$ 127
Consideration transferred, holdback payment	10
Contingent consideration	13
Goodwill	105
Intangible assets	60
Deferred tax liabilities	$ 14
Intangible assets acquired		$ 60

RECEIVABLES - Current Receivables (Details) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022
Receivables [Abstract]
Current customer receivables	$ 3,150	$ 3,112
Non-income based tax receivables	192	174
Other sundry receivables	122	100
Sundry receivables	314	274
Allowance for credit losses	(91)	(91)
Total current receivables – net	3,373	3,295
Chargebacks	$ 200	$ 157

SHARE-BASED COMPENSATION (Tables)

3 Months Ended

Mar. 31, 2023

Share-Based Payment Arrangement [Abstract]

Summary of Weighted Average Grant Date Fair Value and Share-Based Compensation Activity


Weighted Average Grant Date Fair Value
(In dollars)	March 31, 2023
Stock options	$	25
RSUs	72
PSUs	84


Share-Based Compensation Activity
	Stock options						RSUs
	Shares (in thousands)	Weighted average exercise price (in dollars)		Weighted average contractual term (in years)	Intrinsic value (in millions)		Shares (in thousands)	Weighted average grant date fair value (in dollars)		Weighted average contractual term (in years)	Intrinsic value (in millions)
Outstanding as of January 4, 2023(a)	3,738	$	90				3,551	$	58
Granted	2,037	71					1,612	72
Exercised/Vested	(326)	56					(558)	70
Forfeited	(3)	68					(52)	63
Expired	(5)	143					—	—
Outstanding as of March 31, 2023	5,441	$	85	6.6	$	57	4,553	$	63	2.0	$	374
Exercisable as of March 31, 2023	3,182	$	94	4.3	$	33	N/A	N/A		N/A	N/A
Expected to vest	1,681	$	71	9.7	$	18	3,817	$	54	2.0	$	313

Schedule of Stock Options Valuation Assumptions


Key Assumptions in the Black-Scholes Valuation for Stock Options
	March 31, 2023
Risk free rate	3.6		%
Dividend yield	—		%
Expected volatility	26.5		%
Expected term (in years)	6.3
Strike price (in dollars)	$	71

Summary of Share-Based Compensation Expense and Other Share-Based Compensation Data

The following tables present compensation expense and tax impact recognized as well as other share-based compensation data for the three months ended March 31, 2023.


Share-based Compensation Expense
	March 31, 2023



Compensation expense (pre-tax)	$	24
Income tax benefits	(8)
Compensation expense (after-tax)	$	16


Other Share-based Compensation Data
	March 31, 2023
Unrecognized compensation expense (amortized over a weighted average period of 2.0 years)	$	212
Cash received from stock options exercised	18
Intrinsic value of stock options exercised and RSU/PSUs vested	48

ORGANIZATION AND BASIS OF PRESENTATION	3 Months Ended
ORGANIZATION AND BASIS OF PRESENTATION	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
ORGANIZATION AND BASIS OF PRESENTATION	ORGANIZATION AND BASIS OF PRESENTATION BACKGROUND. GE HealthCare Technologies Inc. (“GE HealthCare,” the “Company,” “our,” or “we”) is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator. We operate at the center of the healthcare ecosystem, enabling precision care by increasing health system capacity, enhancing productivity, digitizing healthcare delivery, and improving clinical outcomes while serving patients’ demand for greater efficiency, access, and personalized medicine. Our products, services, and solutions enable clinicians to make more informed decisions quickly and efficiently, improving patient care from diagnosis to therapy to monitoring. On January 3, 2023 (the “Distribution Date”), the General Electric Company (“GE” or “Parent”) completed the previously announced spin-off of GE HealthCare Technologies Inc. (the “Spin-Off”). The Spin-Off was completed through a distribution of approximately 80.1% of the Company’s outstanding common stock to holders of record of GE's common stock as of the close of business on December 16, 2022 (the “Distribution”), which resulted in the issuance of approximately 454 million shares of common stock. Prior to the Distribution, the Company issued 100 shares of common stock in exchange for $1.00, all of which were held by GE as of December 31, 2022. As a result of the Distribution, the Company became an independent public company. Our common stock is listed under the symbol “GEHC” on the Nasdaq Stock Market LLC (“Nasdaq”). During the first quarter of 2023, certain Spin-Off-related adjustments were recorded to reflect transfers from GE, the draw-down of the Term Loan Facility and settlement of Spin-Off transactions with GE, which resulted in the net reduction in Total equity of $2,834 million. These items substantially consisted of: (a) the transfer of certain pension plan liabilities and assets as described in Note 9, “Postretirement Benefit Plans,” (b) the transfer of certain deferred income taxes as described in Note 10, “Income Taxes,” (c) deferred compensation liabilities of $548 million, and (d) employee termination obligations as described in Note 14, “Restructuring and Other Activities.” In connection with the Spin-Off, the Company entered into or adopted several agreements that provide a framework for the relationship between the Company and GE. See Note 18, “Related Parties” for more information on these agreements. Unless the context otherwise requires, references to “GE HealthCare,” “we,” “us,” “our,” and the “Company” refer to (i) GE’s healthcare business prior to the Spin-Off as a carve-out business of GE with related condensed combined financial statements and (ii) GE HealthCare Technologies Inc. and its subsidiaries following the Spin-Off with related condensed consolidated financial statements. BASIS OF PRESENTATION. The condensed consolidated and combined financial statements have been prepared in accordance with United States ("U.S.") generally accepted accounting principles (“U.S. GAAP”) and present the historical results of operations, comprehensive income, and cash flows for the three months ended March 31, 2023 and 2022 and the financial position as of March 31, 2023 and December 31, 2022. It is management’s opinion that these financial statements include all normal and recurring adjustments necessary for a fair presentation of the Company’s financial position and operating results. The following tables are presented in millions of U.S dollars ("USD") unless otherwise stated. All intercompany balances and transactions within the Company have been eliminated in the condensed consolidated and combined financial statements. These financial statements include certain transactions with GE, which are disclosed as related party transactions. See Note 18, “Related Parties” for further information. Prior to the Spin-Off, the condensed combined financial statements were derived from the consolidated financial statements and accounting records of GE including the historical cost basis of assets and liabilities comprising the Company, as well as the historical revenues, direct costs, and allocations of indirect costs attributable to the operations of the Company, using the historical accounting policies applied by GE. The condensed combined financial statements do not purport to reflect what the results of operations, comprehensive income, financial position, or cash flows would have been had the Company operated as a separate, stand-alone entity during the periods presented. The condensed consolidated and combined financial statements should be read in conjunction with the Company’s audited combined financial statements and notes included in our Annual Report on Form 10-K for the year ended December 31, 2022. ESTIMATES AND ASSUMPTIONS. The preparation of the condensed consolidated and combined financial statements in conformity with U.S. GAAP requires management to make estimates based on assumptions about current, and for some estimates, future, economic and market conditions, which affect the reported amounts and related disclosures in the condensed consolidated and combined financial statements. We base our estimates and judgments on historical experience and on various other assumptions and information that we believe to be reasonable under the circumstances. Although our estimates contemplate current and expected future conditions, as applicable, it is reasonably possible that actual conditions could differ from our expectations, which could materially affect our results of operations, financial position, and cash flows. While there has not been a material impact to our accounting estimates as of March 31, 2023 and December 31, 2022 and the results for the three months ended March 31, 2023 and 2022, a number of estimates could be affected by the ongoing COVID-19 pandemic. The severity, magnitude, and duration, as well as the economic consequences of the COVID-19 pandemic, are uncertain and difficult to predict. As a result, our accounting estimates and assumptions may change over time in response to COVID-19. Such changes could result in future impairments of goodwill, intangible assets, long-lived assets, and investment securities, incremental credit losses on receivables, a decrease in the realizability of our tax assets, or an increase in our related obligations as of the time of a relevant measurement event. ACCOUNTING CHANGES. Accounting Standards Codification (“ASC”) Topic 740, Income Taxes, provides that interest and penalties related to unrecognized income tax benefits may either be classified as income tax expense or interest expense in the condensed consolidated statements of operations. In the first quarter of 2023, the Company changed its accounting policy for presentation of interest expense on uncertain tax positions. The interest was previously presented within “Interest and other financial charges – net” and has changed to being presented within “Benefit (provision) for income taxes.” The Company believes this presentation is preferable because the cost is related to income tax matters and this presentation enhances comparability with our peers. The effects of the change in accounting have been prospectively applied to periods beginning in the first quarter of 2023 and were not material to any previously reported periods prior to March 31, 2023. Recent Accounting Pronouncements reflected in the Condensed Consolidated and Combined Financial Statements In September 2022, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2022-04, Liabilities – Supplier Finance Programs (Subtopic 405-50). The ASU requires companies to disclose information about supplier finance programs, including key terms of the program, outstanding confirmed amounts as of the end of the period, a rollforward of such amounts during each annual period, and a description of where the amounts are presented. The new standard does not affect the recognition, measurement, or financial statement presentation of supplier finance obligations. The ASU is effective for fiscal years beginning after December 15, 2022, including interim periods, except for rollforward information, which is effective for fiscal years beginning after December 15, 2023. The Company adopted this guidance on January 1, 2023. See Note 17, “Supplemental Financial Information” for further information. In October 2021, the FASB issued ASU No. 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. The ASU requires companies to apply the definition of a performance obligation under ASC 606, Revenue from Contracts with Customers, to recognize and measure contract assets and contract liabilities relating to contracts with customers acquired in a business combination. Prior to the adoption of this ASU, an acquirer generally recognized assets acquired and liabilities assumed in a business combination, including contract assets and contract liabilities arising from revenue contracts with customers, at fair value on the acquisition date. The ASU results in the acquirer recording acquired contract assets and liabilities on the same basis that would have been recorded by the acquiree before the acquisition under ASC 606. The ASU is effective for fiscal years beginning after December 15, 2022, with early adoption permitted. The Company adopted this guidance on January 1, 2023 using a prospective method, and the adoption did not have a material impact on the condensed consolidated financial statements.